103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB1987 Introduced 2/9/2023, by Sen. Julie A. Morrison SYNOPSIS AS INTRODUCED: 720 ILCS 570/102 from Ch. 56 1/2, par. 1102720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/206 from Ch. 56 1/2, par. 1206 720 ILCS 570/210 from Ch. 56 1/2, par. 1210 Amends the Illinois Controlled Substances Act. Reschedules various Schedule I and Schedule IV controlled substances. Defines "isomer". LRB103 25792 RLC 57149 b A BILL FOR 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB1987 Introduced 2/9/2023, by Sen. Julie A. Morrison SYNOPSIS AS INTRODUCED: 720 ILCS 570/102 from Ch. 56 1/2, par. 1102720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/206 from Ch. 56 1/2, par. 1206 720 ILCS 570/210 from Ch. 56 1/2, par. 1210 720 ILCS 570/102 from Ch. 56 1/2, par. 1102 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/206 from Ch. 56 1/2, par. 1206 720 ILCS 570/210 from Ch. 56 1/2, par. 1210 Amends the Illinois Controlled Substances Act. Reschedules various Schedule I and Schedule IV controlled substances. Defines "isomer". LRB103 25792 RLC 57149 b LRB103 25792 RLC 57149 b A BILL FOR
103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB1987 Introduced 2/9/2023, by Sen. Julie A. Morrison SYNOPSIS AS INTRODUCED:
720 ILCS 570/102 from Ch. 56 1/2, par. 1102720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/206 from Ch. 56 1/2, par. 1206 720 ILCS 570/210 from Ch. 56 1/2, par. 1210 720 ILCS 570/102 from Ch. 56 1/2, par. 1102 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/206 from Ch. 56 1/2, par. 1206 720 ILCS 570/210 from Ch. 56 1/2, par. 1210
720 ILCS 570/102 from Ch. 56 1/2, par. 1102
720 ILCS 570/204 from Ch. 56 1/2, par. 1204
720 ILCS 570/206 from Ch. 56 1/2, par. 1206
720 ILCS 570/210 from Ch. 56 1/2, par. 1210
Amends the Illinois Controlled Substances Act. Reschedules various Schedule I and Schedule IV controlled substances. Defines "isomer".
LRB103 25792 RLC 57149 b LRB103 25792 RLC 57149 b
LRB103 25792 RLC 57149 b
A BILL FOR
SB1987LRB103 25792 RLC 57149 b SB1987 LRB103 25792 RLC 57149 b
SB1987 LRB103 25792 RLC 57149 b
1 AN ACT concerning criminal law.
2 Be it enacted by the People of the State of Illinois,
3 represented in the General Assembly:
4 Section 5. The Illinois Controlled Substances Act is
5 amended by changing Sections 102, 204, 206, and 210 as
6 follows:
7 (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102)
8 Sec. 102. Definitions. As used in this Act, unless the
9 context otherwise requires:
10 (a) "Addict" means any person who habitually uses any
11 drug, chemical, substance or dangerous drug other than alcohol
12 so as to endanger the public morals, health, safety or welfare
13 or who is so far addicted to the use of a dangerous drug or
14 controlled substance other than alcohol as to have lost the
15 power of self control with reference to his or her addiction.
16 (b) "Administer" means the direct application of a
17 controlled substance, whether by injection, inhalation,
18 ingestion, or any other means, to the body of a patient,
19 research subject, or animal (as defined by the Humane
20 Euthanasia in Animal Shelters Act) by:
21 (1) a practitioner (or, in his or her presence, by his
22 or her authorized agent),
23 (2) the patient or research subject pursuant to an
103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB1987 Introduced 2/9/2023, by Sen. Julie A. Morrison SYNOPSIS AS INTRODUCED:
720 ILCS 570/102 from Ch. 56 1/2, par. 1102720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/206 from Ch. 56 1/2, par. 1206 720 ILCS 570/210 from Ch. 56 1/2, par. 1210 720 ILCS 570/102 from Ch. 56 1/2, par. 1102 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/206 from Ch. 56 1/2, par. 1206 720 ILCS 570/210 from Ch. 56 1/2, par. 1210
720 ILCS 570/102 from Ch. 56 1/2, par. 1102
720 ILCS 570/204 from Ch. 56 1/2, par. 1204
720 ILCS 570/206 from Ch. 56 1/2, par. 1206
720 ILCS 570/210 from Ch. 56 1/2, par. 1210
Amends the Illinois Controlled Substances Act. Reschedules various Schedule I and Schedule IV controlled substances. Defines "isomer".
LRB103 25792 RLC 57149 b LRB103 25792 RLC 57149 b
LRB103 25792 RLC 57149 b
A BILL FOR
720 ILCS 570/102 from Ch. 56 1/2, par. 1102
720 ILCS 570/204 from Ch. 56 1/2, par. 1204
720 ILCS 570/206 from Ch. 56 1/2, par. 1206
720 ILCS 570/210 from Ch. 56 1/2, par. 1210
LRB103 25792 RLC 57149 b
SB1987 LRB103 25792 RLC 57149 b
SB1987- 2 -LRB103 25792 RLC 57149 b SB1987 - 2 - LRB103 25792 RLC 57149 b
SB1987 - 2 - LRB103 25792 RLC 57149 b
1 order, or
2 (3) a euthanasia technician as defined by the Humane
3 Euthanasia in Animal Shelters Act.
4 (c) "Agent" means an authorized person who acts on behalf
5 of or at the direction of a manufacturer, distributor,
6 dispenser, prescriber, or practitioner. It does not include a
7 common or contract carrier, public warehouseman or employee of
8 the carrier or warehouseman.
9 (c-1) "Anabolic Steroids" means any drug or hormonal
10 substance, chemically and pharmacologically related to
11 testosterone (other than estrogens, progestins,
12 corticosteroids, and dehydroepiandrosterone), and includes:
13 (i) 3[beta],17-dihydroxy-5a-androstane,
14 (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,
15 (iii) 5[alpha]-androstan-3,17-dione,
16 (iv) 1-androstenediol (3[beta],
17 17[beta]-dihydroxy-5[alpha]-androst-1-ene),
18 (v) 1-androstenediol (3[alpha],
19 17[beta]-dihydroxy-5[alpha]-androst-1-ene),
20 (vi) 4-androstenediol
21 (3[beta],17[beta]-dihydroxy-androst-4-ene),
22 (vii) 5-androstenediol
23 (3[beta],17[beta]-dihydroxy-androst-5-ene),
24 (viii) 1-androstenedione
25 ([5alpha]-androst-1-en-3,17-dione),
26 (ix) 4-androstenedione
SB1987 - 2 - LRB103 25792 RLC 57149 b
SB1987- 3 -LRB103 25792 RLC 57149 b SB1987 - 3 - LRB103 25792 RLC 57149 b
SB1987 - 3 - LRB103 25792 RLC 57149 b
1 (androst-4-en-3,17-dione),
2 (x) 5-androstenedione
3 (androst-5-en-3,17-dione),
4 (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-
5 hydroxyandrost-4-en-3-one),
6 (xii) boldenone (17[beta]-hydroxyandrost-
7 1,4,-diene-3-one),
8 (xiii) boldione (androsta-1,4-
9 diene-3,17-dione),
10 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17
11 [beta]-hydroxyandrost-4-en-3-one),
12 (xv) clostebol (4-chloro-17[beta]-
13 hydroxyandrost-4-en-3-one),
14 (xvi) dehydrochloromethyltestosterone (4-chloro-
15 17[beta]-hydroxy-17[alpha]-methyl-
16 androst-1,4-dien-3-one),
17 (xvii) desoxymethyltestosterone
18 (17[alpha]-methyl-5[alpha]
19 -androst-2-en-17[beta]-ol)(a.k.a., madol),
20 (xviii) [delta]1-dihydrotestosterone (a.k.a.
21 '1-testosterone') (17[beta]-hydroxy-
22 5[alpha]-androst-1-en-3-one),
23 (xix) 4-dihydrotestosterone (17[beta]-hydroxy-
24 androstan-3-one),
25 (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-
26 5[alpha]-androstan-3-one),
SB1987 - 3 - LRB103 25792 RLC 57149 b
SB1987- 4 -LRB103 25792 RLC 57149 b SB1987 - 4 - LRB103 25792 RLC 57149 b
SB1987 - 4 - LRB103 25792 RLC 57149 b
1 (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-
2 hydroxyestr-4-ene),
3 (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-
4 1[beta],17[beta]-dihydroxyandrost-4-en-3-one),
5 (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],
6 17[beta]-dihydroxyandrost-1,4-dien-3-one),
7 (xxiv) furazabol (17[alpha]-methyl-17[beta]-
8 hydroxyandrostano[2,3-c]-furazan),
9 (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one,
10 (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-
11 androst-4-en-3-one),
12 (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-
13 dihydroxy-estr-4-en-3-one),
14 (xxviii) mestanolone (17[alpha]-methyl-17[beta]-
15 hydroxy-5-androstan-3-one),
16 (xxix) mesterolone (1amethyl-17[beta]-hydroxy-
17 [5a]-androstan-3-one),
18 (xxx) methandienone (17[alpha]-methyl-17[beta]-
19 hydroxyandrost-1,4-dien-3-one),
20 (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-
21 dihydroxyandrost-5-ene),
22 (xxxii) methenolone (1-methyl-17[beta]-hydroxy-
23 5[alpha]-androst-1-en-3-one),
24 (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-
25 dihydroxy-5a-androstane,
26 (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy
SB1987 - 4 - LRB103 25792 RLC 57149 b
SB1987- 5 -LRB103 25792 RLC 57149 b SB1987 - 5 - LRB103 25792 RLC 57149 b
SB1987 - 5 - LRB103 25792 RLC 57149 b
1 -5a-androstane,
2 (xxxv) 17[alpha]-methyl-3[beta],17[beta]-
3 dihydroxyandrost-4-ene),
4 (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-
5 methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),
6 (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-
7 hydroxyestra-4,9(10)-dien-3-one),
8 (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-
9 hydroxyestra-4,9-11-trien-3-one),
10 (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-
11 hydroxyandrost-4-en-3-one),
12 (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-
13 hydroxyestr-4-en-3-one),
14 (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
15 (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-
16 androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl-
17 1-testosterone'),
18 (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),
19 (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-
20 dihydroxyestr-4-ene),
21 (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-
22 dihydroxyestr-4-ene),
23 (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-
24 dihydroxyestr-5-ene),
25 (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-
26 dihydroxyestr-5-ene),
SB1987 - 5 - LRB103 25792 RLC 57149 b
SB1987- 6 -LRB103 25792 RLC 57149 b SB1987 - 6 - LRB103 25792 RLC 57149 b
SB1987 - 6 - LRB103 25792 RLC 57149 b
1 (xlvii) 19-nor-4,9(10)-androstadienedione
2 (estra-4,9(10)-diene-3,17-dione),
3 (xlviii) 19-nor-4-androstenedione (estr-4-
4 en-3,17-dione),
5 (xlix) 19-nor-5-androstenedione (estr-5-
6 en-3,17-dione),
7 (l) norbolethone (13[beta], 17a-diethyl-17[beta]-
8 hydroxygon-4-en-3-one),
9 (li) norclostebol (4-chloro-17[beta]-
10 hydroxyestr-4-en-3-one),
11 (lii) norethandrolone (17[alpha]-ethyl-17[beta]-
12 hydroxyestr-4-en-3-one),
13 (liii) normethandrolone (17[alpha]-methyl-17[beta]-
14 hydroxyestr-4-en-3-one),
15 (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-
16 2-oxa-5[alpha]-androstan-3-one),
17 (lv) oxymesterone (17[alpha]-methyl-4,17[beta]-
18 dihydroxyandrost-4-en-3-one),
19 (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-
20 17[beta]-hydroxy-(5[alpha]-androstan-3-one),
21 (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-
22 (5[alpha]-androst-2-eno[3,2-c]-pyrazole),
23 (lviii) stenbolone (17[beta]-hydroxy-2-methyl-
24 (5[alpha]-androst-1-en-3-one),
25 (lix) testolactone (13-hydroxy-3-oxo-13,17-
26 secoandrosta-1,4-dien-17-oic
SB1987 - 6 - LRB103 25792 RLC 57149 b
SB1987- 7 -LRB103 25792 RLC 57149 b SB1987 - 7 - LRB103 25792 RLC 57149 b
SB1987 - 7 - LRB103 25792 RLC 57149 b
1 acid lactone),
2 (lx) testosterone (17[beta]-hydroxyandrost-
3 4-en-3-one),
4 (lxi) tetrahydrogestrinone (13[beta], 17[alpha]-
5 diethyl-17[beta]-hydroxygon-
6 4,9,11-trien-3-one),
7 (lxii) trenbolone (17[beta]-hydroxyestr-4,9,
8 11-trien-3-one).
9 Any person who is otherwise lawfully in possession of an
10 anabolic steroid, or who otherwise lawfully manufactures,
11 distributes, dispenses, delivers, or possesses with intent to
12 deliver an anabolic steroid, which anabolic steroid is
13 expressly intended for and lawfully allowed to be administered
14 through implants to livestock or other nonhuman species, and
15 which is approved by the Secretary of Health and Human
16 Services for such administration, and which the person intends
17 to administer or have administered through such implants,
18 shall not be considered to be in unauthorized possession or to
19 unlawfully manufacture, distribute, dispense, deliver, or
20 possess with intent to deliver such anabolic steroid for
21 purposes of this Act.
22 (d) "Administration" means the Drug Enforcement
23 Administration, United States Department of Justice, or its
24 successor agency.
25 (d-5) "Clinical Director, Prescription Monitoring Program"
26 means a Department of Human Services administrative employee
SB1987 - 7 - LRB103 25792 RLC 57149 b
SB1987- 8 -LRB103 25792 RLC 57149 b SB1987 - 8 - LRB103 25792 RLC 57149 b
SB1987 - 8 - LRB103 25792 RLC 57149 b
1 licensed to either prescribe or dispense controlled substances
2 who shall run the clinical aspects of the Department of Human
3 Services Prescription Monitoring Program and its Prescription
4 Information Library.
5 (d-10) "Compounding" means the preparation and mixing of
6 components, excluding flavorings, (1) as the result of a
7 prescriber's prescription drug order or initiative based on
8 the prescriber-patient-pharmacist relationship in the course
9 of professional practice or (2) for the purpose of, or
10 incident to, research, teaching, or chemical analysis and not
11 for sale or dispensing. "Compounding" includes the preparation
12 of drugs or devices in anticipation of receiving prescription
13 drug orders based on routine, regularly observed dispensing
14 patterns. Commercially available products may be compounded
15 for dispensing to individual patients only if both of the
16 following conditions are met: (i) the commercial product is
17 not reasonably available from normal distribution channels in
18 a timely manner to meet the patient's needs and (ii) the
19 prescribing practitioner has requested that the drug be
20 compounded.
21 (e) "Control" means to add a drug or other substance, or
22 immediate precursor, to a Schedule whether by transfer from
23 another Schedule or otherwise.
24 (f) "Controlled Substance" means (i) a drug, substance,
25 immediate precursor, or synthetic drug in the Schedules of
26 Article II of this Act or (ii) a drug or other substance, or
SB1987 - 8 - LRB103 25792 RLC 57149 b
SB1987- 9 -LRB103 25792 RLC 57149 b SB1987 - 9 - LRB103 25792 RLC 57149 b
SB1987 - 9 - LRB103 25792 RLC 57149 b
1 immediate precursor, designated as a controlled substance by
2 the Department through administrative rule. The term does not
3 include distilled spirits, wine, malt beverages, or tobacco,
4 as those terms are defined or used in the Liquor Control Act of
5 1934 and the Tobacco Products Tax Act of 1995.
6 (f-5) "Controlled substance analog" means a substance:
7 (1) the chemical structure of which is substantially
8 similar to the chemical structure of a controlled
9 substance in Schedule I or II;
10 (2) which has a stimulant, depressant, or
11 hallucinogenic effect on the central nervous system that
12 is substantially similar to or greater than the stimulant,
13 depressant, or hallucinogenic effect on the central
14 nervous system of a controlled substance in Schedule I or
15 II; or
16 (3) with respect to a particular person, which such
17 person represents or intends to have a stimulant,
18 depressant, or hallucinogenic effect on the central
19 nervous system that is substantially similar to or greater
20 than the stimulant, depressant, or hallucinogenic effect
21 on the central nervous system of a controlled substance in
22 Schedule I or II.
23 (g) "Counterfeit substance" means a controlled substance,
24 which, or the container or labeling of which, without
25 authorization bears the trademark, trade name, or other
26 identifying mark, imprint, number or device, or any likeness
SB1987 - 9 - LRB103 25792 RLC 57149 b
SB1987- 10 -LRB103 25792 RLC 57149 b SB1987 - 10 - LRB103 25792 RLC 57149 b
SB1987 - 10 - LRB103 25792 RLC 57149 b
1 thereof, of a manufacturer, distributor, or dispenser other
2 than the person who in fact manufactured, distributed, or
3 dispensed the substance.
4 (h) "Deliver" or "delivery" means the actual, constructive
5 or attempted transfer of possession of a controlled substance,
6 with or without consideration, whether or not there is an
7 agency relationship. "Deliver" or "delivery" does not include
8 the donation of drugs to the extent permitted under the
9 Illinois Drug Reuse Opportunity Program Act.
10 (i) "Department" means the Illinois Department of Human
11 Services (as successor to the Department of Alcoholism and
12 Substance Abuse) or its successor agency.
13 (j) (Blank).
14 (k) "Department of Corrections" means the Department of
15 Corrections of the State of Illinois or its successor agency.
16 (l) "Department of Financial and Professional Regulation"
17 means the Department of Financial and Professional Regulation
18 of the State of Illinois or its successor agency.
19 (m) "Depressant" means any drug that (i) causes an overall
20 depression of central nervous system functions, (ii) causes
21 impaired consciousness and awareness, and (iii) can be
22 habit-forming or lead to a substance abuse problem, including,
23 but not limited to, alcohol, cannabis and its active
24 principles and their analogs, benzodiazepines and their
25 analogs, barbiturates and their analogs, opioids (natural and
26 synthetic) and their analogs, and chloral hydrate and similar
SB1987 - 10 - LRB103 25792 RLC 57149 b
SB1987- 11 -LRB103 25792 RLC 57149 b SB1987 - 11 - LRB103 25792 RLC 57149 b
SB1987 - 11 - LRB103 25792 RLC 57149 b
1 sedative hypnotics.
2 (n) (Blank).
3 (o) "Director" means the Director of the Illinois State
4 Police or his or her designated agents.
5 (p) "Dispense" means to deliver a controlled substance to
6 an ultimate user or research subject by or pursuant to the
7 lawful order of a prescriber, including the prescribing,
8 administering, packaging, labeling, or compounding necessary
9 to prepare the substance for that delivery.
10 (q) "Dispenser" means a practitioner who dispenses.
11 (r) "Distribute" means to deliver, other than by
12 administering or dispensing, a controlled substance.
13 (s) "Distributor" means a person who distributes.
14 (t) "Drug" means (1) substances recognized as drugs in the
15 official United States Pharmacopoeia, Official Homeopathic
16 Pharmacopoeia of the United States, or official National
17 Formulary, or any supplement to any of them; (2) substances
18 intended for use in diagnosis, cure, mitigation, treatment, or
19 prevention of disease in man or animals; (3) substances (other
20 than food) intended to affect the structure of any function of
21 the body of man or animals and (4) substances intended for use
22 as a component of any article specified in clause (1), (2), or
23 (3) of this subsection. It does not include devices or their
24 components, parts, or accessories.
25 (t-3) "Electronic health record" or "EHR" means an
26 electronic record of health-related information on an
SB1987 - 11 - LRB103 25792 RLC 57149 b
SB1987- 12 -LRB103 25792 RLC 57149 b SB1987 - 12 - LRB103 25792 RLC 57149 b
SB1987 - 12 - LRB103 25792 RLC 57149 b
1 individual that is created, gathered, managed, and consulted
2 by authorized health care clinicians and staff.
3 (t-3.5) "Electronic health record system" or "EHR system"
4 means any computer-based system or combination of federally
5 certified Health IT Modules (defined at 42 CFR 170.102 or its
6 successor) used as a repository for electronic health records
7 and accessed or updated by a prescriber or authorized
8 surrogate in the ordinary course of his or her medical
9 practice. For purposes of connecting to the Prescription
10 Information Library maintained by the Bureau of Pharmacy and
11 Clinical Support Systems or its successor, an EHR system may
12 connect to the Prescription Information Library directly or
13 through all or part of a computer program or system that is a
14 federally certified Health IT Module maintained by a third
15 party and used by the EHR system to secure access to the
16 database.
17 (t-4) "Emergency medical services personnel" has the
18 meaning ascribed to it in the Emergency Medical Services (EMS)
19 Systems Act.
20 (t-5) "Euthanasia agency" means an entity certified by the
21 Department of Financial and Professional Regulation for the
22 purpose of animal euthanasia that holds an animal control
23 facility license or animal shelter license under the Animal
24 Welfare Act. A euthanasia agency is authorized to purchase,
25 store, possess, and utilize Schedule II nonnarcotic and
26 Schedule III nonnarcotic drugs for the sole purpose of animal
SB1987 - 12 - LRB103 25792 RLC 57149 b
SB1987- 13 -LRB103 25792 RLC 57149 b SB1987 - 13 - LRB103 25792 RLC 57149 b
SB1987 - 13 - LRB103 25792 RLC 57149 b
1 euthanasia.
2 (t-10) "Euthanasia drugs" means Schedule II or Schedule
3 III substances (nonnarcotic controlled substances) that are
4 used by a euthanasia agency for the purpose of animal
5 euthanasia.
6 (u) "Good faith" means the prescribing or dispensing of a
7 controlled substance by a practitioner in the regular course
8 of professional treatment to or for any person who is under his
9 or her treatment for a pathology or condition other than that
10 individual's physical or psychological dependence upon or
11 addiction to a controlled substance, except as provided
12 herein: and application of the term to a pharmacist shall mean
13 the dispensing of a controlled substance pursuant to the
14 prescriber's order which in the professional judgment of the
15 pharmacist is lawful. The pharmacist shall be guided by
16 accepted professional standards, including, but not limited
17 to, the following, in making the judgment:
18 (1) lack of consistency of prescriber-patient
19 relationship,
20 (2) frequency of prescriptions for same drug by one
21 prescriber for large numbers of patients,
22 (3) quantities beyond those normally prescribed,
23 (4) unusual dosages (recognizing that there may be
24 clinical circumstances where more or less than the usual
25 dose may be used legitimately),
26 (5) unusual geographic distances between patient,
SB1987 - 13 - LRB103 25792 RLC 57149 b
SB1987- 14 -LRB103 25792 RLC 57149 b SB1987 - 14 - LRB103 25792 RLC 57149 b
SB1987 - 14 - LRB103 25792 RLC 57149 b
1 pharmacist and prescriber,
2 (6) consistent prescribing of habit-forming drugs.
3 (u-0.5) "Hallucinogen" means a drug that causes markedly
4 altered sensory perception leading to hallucinations of any
5 type.
6 (u-1) "Home infusion services" means services provided by
7 a pharmacy in compounding solutions for direct administration
8 to a patient in a private residence, long-term care facility,
9 or hospice setting by means of parenteral, intravenous,
10 intramuscular, subcutaneous, or intraspinal infusion.
11 (u-5) "Illinois State Police" means the Illinois State
12 Police or its successor agency.
13 (v) "Immediate precursor" means a substance:
14 (1) which the Department has found to be and by rule
15 designated as being a principal compound used, or produced
16 primarily for use, in the manufacture of a controlled
17 substance;
18 (2) which is an immediate chemical intermediary used
19 or likely to be used in the manufacture of such controlled
20 substance; and
21 (3) the control of which is necessary to prevent,
22 curtail or limit the manufacture of such controlled
23 substance.
24 (w) "Instructional activities" means the acts of teaching,
25 educating or instructing by practitioners using controlled
26 substances within educational facilities approved by the State
SB1987 - 14 - LRB103 25792 RLC 57149 b
SB1987- 15 -LRB103 25792 RLC 57149 b SB1987 - 15 - LRB103 25792 RLC 57149 b
SB1987 - 15 - LRB103 25792 RLC 57149 b
1 Board of Education or its successor agency.
2 (w-1) "Isomer" means optical isomer unless specifically
3 described in this Act.
4 (x) "Local authorities" means a duly organized State,
5 County or Municipal peace unit or police force.
6 (y) "Look-alike substance" means a substance, other than a
7 controlled substance which (1) by overall dosage unit
8 appearance, including shape, color, size, markings or lack
9 thereof, taste, consistency, or any other identifying physical
10 characteristic of the substance, would lead a reasonable
11 person to believe that the substance is a controlled
12 substance, or (2) is expressly or impliedly represented to be
13 a controlled substance or is distributed under circumstances
14 which would lead a reasonable person to believe that the
15 substance is a controlled substance. For the purpose of
16 determining whether the representations made or the
17 circumstances of the distribution would lead a reasonable
18 person to believe the substance to be a controlled substance
19 under this clause (2) of subsection (y), the court or other
20 authority may consider the following factors in addition to
21 any other factor that may be relevant:
22 (a) statements made by the owner or person in control
23 of the substance concerning its nature, use or effect;
24 (b) statements made to the buyer or recipient that the
25 substance may be resold for profit;
26 (c) whether the substance is packaged in a manner
SB1987 - 15 - LRB103 25792 RLC 57149 b
SB1987- 16 -LRB103 25792 RLC 57149 b SB1987 - 16 - LRB103 25792 RLC 57149 b
SB1987 - 16 - LRB103 25792 RLC 57149 b
1 normally used for the illegal distribution of controlled
2 substances;
3 (d) whether the distribution or attempted distribution
4 included an exchange of or demand for money or other
5 property as consideration, and whether the amount of the
6 consideration was substantially greater than the
7 reasonable retail market value of the substance.
8 Clause (1) of this subsection (y) shall not apply to a
9 noncontrolled substance in its finished dosage form that was
10 initially introduced into commerce prior to the initial
11 introduction into commerce of a controlled substance in its
12 finished dosage form which it may substantially resemble.
13 Nothing in this subsection (y) prohibits the dispensing or
14 distributing of noncontrolled substances by persons authorized
15 to dispense and distribute controlled substances under this
16 Act, provided that such action would be deemed to be carried
17 out in good faith under subsection (u) if the substances
18 involved were controlled substances.
19 Nothing in this subsection (y) or in this Act prohibits
20 the manufacture, preparation, propagation, compounding,
21 processing, packaging, advertising or distribution of a drug
22 or drugs by any person registered pursuant to Section 510 of
23 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
24 (y-1) "Mail-order pharmacy" means a pharmacy that is
25 located in a state of the United States that delivers,
26 dispenses or distributes, through the United States Postal
SB1987 - 16 - LRB103 25792 RLC 57149 b
SB1987- 17 -LRB103 25792 RLC 57149 b SB1987 - 17 - LRB103 25792 RLC 57149 b
SB1987 - 17 - LRB103 25792 RLC 57149 b
1 Service or other common carrier, to Illinois residents, any
2 substance which requires a prescription.
3 (z) "Manufacture" means the production, preparation,
4 propagation, compounding, conversion or processing of a
5 controlled substance other than methamphetamine, either
6 directly or indirectly, by extraction from substances of
7 natural origin, or independently by means of chemical
8 synthesis, or by a combination of extraction and chemical
9 synthesis, and includes any packaging or repackaging of the
10 substance or labeling of its container, except that this term
11 does not include:
12 (1) by an ultimate user, the preparation or
13 compounding of a controlled substance for his or her own
14 use;
15 (2) by a practitioner, or his or her authorized agent
16 under his or her supervision, the preparation,
17 compounding, packaging, or labeling of a controlled
18 substance:
19 (a) as an incident to his or her administering or
20 dispensing of a controlled substance in the course of
21 his or her professional practice; or
22 (b) as an incident to lawful research, teaching or
23 chemical analysis and not for sale; or
24 (3) the packaging, repackaging, or labeling of drugs
25 only to the extent permitted under the Illinois Drug Reuse
26 Opportunity Program Act.
SB1987 - 17 - LRB103 25792 RLC 57149 b
SB1987- 18 -LRB103 25792 RLC 57149 b SB1987 - 18 - LRB103 25792 RLC 57149 b
SB1987 - 18 - LRB103 25792 RLC 57149 b
1 (z-1) (Blank).
2 (z-5) "Medication shopping" means the conduct prohibited
3 under subsection (a) of Section 314.5 of this Act.
4 (z-10) "Mid-level practitioner" means (i) a physician
5 assistant who has been delegated authority to prescribe
6 through a written delegation of authority by a physician
7 licensed to practice medicine in all of its branches, in
8 accordance with Section 7.5 of the Physician Assistant
9 Practice Act of 1987, (ii) an advanced practice registered
10 nurse who has been delegated authority to prescribe through a
11 written delegation of authority by a physician licensed to
12 practice medicine in all of its branches or by a podiatric
13 physician, in accordance with Section 65-40 of the Nurse
14 Practice Act, (iii) an advanced practice registered nurse
15 certified as a nurse practitioner, nurse midwife, or clinical
16 nurse specialist who has been granted authority to prescribe
17 by a hospital affiliate in accordance with Section 65-45 of
18 the Nurse Practice Act, (iv) an animal euthanasia agency, or
19 (v) a prescribing psychologist.
20 (aa) "Narcotic drug" means any of the following, whether
21 produced directly or indirectly by extraction from substances
22 of vegetable origin, or independently by means of chemical
23 synthesis, or by a combination of extraction and chemical
24 synthesis:
25 (1) opium, opiates, derivatives of opium and opiates,
26 including their isomers, esters, ethers, salts, and salts
SB1987 - 18 - LRB103 25792 RLC 57149 b
SB1987- 19 -LRB103 25792 RLC 57149 b SB1987 - 19 - LRB103 25792 RLC 57149 b
SB1987 - 19 - LRB103 25792 RLC 57149 b
1 of isomers, esters, and ethers, whenever the existence of
2 such isomers, esters, ethers, and salts is possible within
3 the specific chemical designation; however the term
4 "narcotic drug" does not include the isoquinoline
5 alkaloids of opium;
6 (2) (blank);
7 (3) opium poppy and poppy straw;
8 (4) coca leaves, except coca leaves and extracts of
9 coca leaves from which substantially all of the cocaine
10 and ecgonine, and their isomers, derivatives and salts,
11 have been removed;
12 (5) cocaine, its salts, optical and geometric isomers,
13 and salts of isomers;
14 (6) ecgonine, its derivatives, their salts, isomers,
15 and salts of isomers;
16 (7) any compound, mixture, or preparation which
17 contains any quantity of any of the substances referred to
18 in subparagraphs (1) through (6).
19 (bb) "Nurse" means a registered nurse licensed under the
20 Nurse Practice Act.
21 (cc) (Blank).
22 (dd) "Opiate" means any substance having an addiction
23 forming or addiction sustaining liability similar to morphine
24 or being capable of conversion into a drug having addiction
25 forming or addiction sustaining liability.
26 (ee) "Opium poppy" means the plant of the species Papaver
SB1987 - 19 - LRB103 25792 RLC 57149 b
SB1987- 20 -LRB103 25792 RLC 57149 b SB1987 - 20 - LRB103 25792 RLC 57149 b
SB1987 - 20 - LRB103 25792 RLC 57149 b
1 somniferum L., except its seeds.
2 (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
3 solution or other liquid form of medication intended for
4 administration by mouth, but the term does not include a form
5 of medication intended for buccal, sublingual, or transmucosal
6 administration.
7 (ff) "Parole and Pardon Board" means the Parole and Pardon
8 Board of the State of Illinois or its successor agency.
9 (gg) "Person" means any individual, corporation,
10 mail-order pharmacy, government or governmental subdivision or
11 agency, business trust, estate, trust, partnership or
12 association, or any other entity.
13 (hh) "Pharmacist" means any person who holds a license or
14 certificate of registration as a registered pharmacist, a
15 local registered pharmacist or a registered assistant
16 pharmacist under the Pharmacy Practice Act.
17 (ii) "Pharmacy" means any store, ship or other place in
18 which pharmacy is authorized to be practiced under the
19 Pharmacy Practice Act.
20 (ii-5) "Pharmacy shopping" means the conduct prohibited
21 under subsection (b) of Section 314.5 of this Act.
22 (ii-10) "Physician" (except when the context otherwise
23 requires) means a person licensed to practice medicine in all
24 of its branches.
25 (jj) "Poppy straw" means all parts, except the seeds, of
26 the opium poppy, after mowing.
SB1987 - 20 - LRB103 25792 RLC 57149 b
SB1987- 21 -LRB103 25792 RLC 57149 b SB1987 - 21 - LRB103 25792 RLC 57149 b
SB1987 - 21 - LRB103 25792 RLC 57149 b
1 (kk) "Practitioner" means a physician licensed to practice
2 medicine in all its branches, dentist, optometrist, podiatric
3 physician, veterinarian, scientific investigator, pharmacist,
4 physician assistant, advanced practice registered nurse,
5 licensed practical nurse, registered nurse, emergency medical
6 services personnel, hospital, laboratory, or pharmacy, or
7 other person licensed, registered, or otherwise lawfully
8 permitted by the United States or this State to distribute,
9 dispense, conduct research with respect to, administer or use
10 in teaching or chemical analysis, a controlled substance in
11 the course of professional practice or research.
12 (ll) "Pre-printed prescription" means a written
13 prescription upon which the designated drug has been indicated
14 prior to the time of issuance; the term does not mean a written
15 prescription that is individually generated by machine or
16 computer in the prescriber's office.
17 (mm) "Prescriber" means a physician licensed to practice
18 medicine in all its branches, dentist, optometrist,
19 prescribing psychologist licensed under Section 4.2 of the
20 Clinical Psychologist Licensing Act with prescriptive
21 authority delegated under Section 4.3 of the Clinical
22 Psychologist Licensing Act, podiatric physician, or
23 veterinarian who issues a prescription, a physician assistant
24 who issues a prescription for a controlled substance in
25 accordance with Section 303.05, a written delegation, and a
26 written collaborative agreement required under Section 7.5 of
SB1987 - 21 - LRB103 25792 RLC 57149 b
SB1987- 22 -LRB103 25792 RLC 57149 b SB1987 - 22 - LRB103 25792 RLC 57149 b
SB1987 - 22 - LRB103 25792 RLC 57149 b
1 the Physician Assistant Practice Act of 1987, an advanced
2 practice registered nurse with prescriptive authority
3 delegated under Section 65-40 of the Nurse Practice Act and in
4 accordance with Section 303.05, a written delegation, and a
5 written collaborative agreement under Section 65-35 of the
6 Nurse Practice Act, an advanced practice registered nurse
7 certified as a nurse practitioner, nurse midwife, or clinical
8 nurse specialist who has been granted authority to prescribe
9 by a hospital affiliate in accordance with Section 65-45 of
10 the Nurse Practice Act and in accordance with Section 303.05,
11 or an advanced practice registered nurse certified as a nurse
12 practitioner, nurse midwife, or clinical nurse specialist who
13 has full practice authority pursuant to Section 65-43 of the
14 Nurse Practice Act.
15 (nn) "Prescription" means a written, facsimile, or oral
16 order, or an electronic order that complies with applicable
17 federal requirements, of a physician licensed to practice
18 medicine in all its branches, dentist, podiatric physician or
19 veterinarian for any controlled substance, of an optometrist
20 in accordance with Section 15.1 of the Illinois Optometric
21 Practice Act of 1987, of a prescribing psychologist licensed
22 under Section 4.2 of the Clinical Psychologist Licensing Act
23 with prescriptive authority delegated under Section 4.3 of the
24 Clinical Psychologist Licensing Act, of a physician assistant
25 for a controlled substance in accordance with Section 303.05,
26 a written delegation, and a written collaborative agreement
SB1987 - 22 - LRB103 25792 RLC 57149 b
SB1987- 23 -LRB103 25792 RLC 57149 b SB1987 - 23 - LRB103 25792 RLC 57149 b
SB1987 - 23 - LRB103 25792 RLC 57149 b
1 required under Section 7.5 of the Physician Assistant Practice
2 Act of 1987, of an advanced practice registered nurse with
3 prescriptive authority delegated under Section 65-40 of the
4 Nurse Practice Act who issues a prescription for a controlled
5 substance in accordance with Section 303.05, a written
6 delegation, and a written collaborative agreement under
7 Section 65-35 of the Nurse Practice Act, of an advanced
8 practice registered nurse certified as a nurse practitioner,
9 nurse midwife, or clinical nurse specialist who has been
10 granted authority to prescribe by a hospital affiliate in
11 accordance with Section 65-45 of the Nurse Practice Act and in
12 accordance with Section 303.05 when required by law, or of an
13 advanced practice registered nurse certified as a nurse
14 practitioner, nurse midwife, or clinical nurse specialist who
15 has full practice authority pursuant to Section 65-43 of the
16 Nurse Practice Act.
17 (nn-5) "Prescription Information Library" (PIL) means an
18 electronic library that contains reported controlled substance
19 data.
20 (nn-10) "Prescription Monitoring Program" (PMP) means the
21 entity that collects, tracks, and stores reported data on
22 controlled substances and select drugs pursuant to Section
23 316.
24 (oo) "Production" or "produce" means manufacture,
25 planting, cultivating, growing, or harvesting of a controlled
26 substance other than methamphetamine.
SB1987 - 23 - LRB103 25792 RLC 57149 b
SB1987- 24 -LRB103 25792 RLC 57149 b SB1987 - 24 - LRB103 25792 RLC 57149 b
SB1987 - 24 - LRB103 25792 RLC 57149 b
1 (pp) "Registrant" means every person who is required to
2 register under Section 302 of this Act.
3 (qq) "Registry number" means the number assigned to each
4 person authorized to handle controlled substances under the
5 laws of the United States and of this State.
6 (qq-5) "Secretary" means, as the context requires, either
7 the Secretary of the Department or the Secretary of the
8 Department of Financial and Professional Regulation, and the
9 Secretary's designated agents.
10 (rr) "State" includes the State of Illinois and any state,
11 district, commonwealth, territory, insular possession thereof,
12 and any area subject to the legal authority of the United
13 States of America.
14 (rr-5) "Stimulant" means any drug that (i) causes an
15 overall excitation of central nervous system functions, (ii)
16 causes impaired consciousness and awareness, and (iii) can be
17 habit-forming or lead to a substance abuse problem, including,
18 but not limited to, amphetamines and their analogs,
19 methylphenidate and its analogs, cocaine, and phencyclidine
20 and its analogs.
21 (rr-10) "Synthetic drug" includes, but is not limited to,
22 any synthetic cannabinoids or piperazines or any synthetic
23 cathinones as provided for in Schedule I.
24 (ss) "Ultimate user" means a person who lawfully possesses
25 a controlled substance for his or her own use or for the use of
26 a member of his or her household or for administering to an
SB1987 - 24 - LRB103 25792 RLC 57149 b
SB1987- 25 -LRB103 25792 RLC 57149 b SB1987 - 25 - LRB103 25792 RLC 57149 b
SB1987 - 25 - LRB103 25792 RLC 57149 b
1 animal owned by him or her or by a member of his or her
2 household.
3 (Source: P.A. 101-666, eff. 1-1-22; 102-389, eff. 1-1-22;
4 102-538, eff. 8-20-21; 102-813, eff. 5-13-22.)
5 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)
6 Sec. 204. (a) The controlled substances listed in this
7 Section are included in Schedule I.
8 (b) Unless specifically excepted or unless listed in
9 another schedule, any of the following opiates, including
10 their isomers, esters, ethers, salts, and salts of isomers,
11 esters, and ethers, whenever the existence of such isomers,
12 esters, ethers and salts is possible within the specific
13 chemical designation:
14 (1) Acetylmethadol;
15 (1.1) Acetyl-alpha-methylfentanyl
16 (N-[1-(1-methyl-2-phenethyl)-
17 4-piperidinyl]-N-phenylacetamide);
18 (2) Allylprodine;
19 (3) Alphacetylmethadol, except
20 levo-alphacetylmethadol (also known as levo-alpha-
21 acetylmethadol, levomethadyl acetate, or LAAM);
22 (4) Alphameprodine;
23 (5) Alphamethadol;
24 (6) Alpha-methylfentanyl
25 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
SB1987 - 25 - LRB103 25792 RLC 57149 b
SB1987- 26 -LRB103 25792 RLC 57149 b SB1987 - 26 - LRB103 25792 RLC 57149 b
SB1987 - 26 - LRB103 25792 RLC 57149 b
1 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
2 propanilido) piperidine;
3 (6.1) Alpha-methylthiofentanyl
4 (N-[1-methyl-2-(2-thienyl)ethyl-
5 4-piperidinyl]-N-phenylpropanamide);
6 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
7 (7.1) PEPAP
8 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
9 (8) Benzethidine;
10 (9) Betacetylmethadol;
11 (9.1) Beta-hydroxyfentanyl
12 (N-[1-(2-hydroxy-2-phenethyl)-
13 4-piperidinyl]-N-phenylpropanamide);
14 (10) Betameprodine;
15 (11) Betamethadol;
16 (12) Betaprodine;
17 (12.1) Brorphine;
18 (13) Clonitazene;
19 (14) Dextromoramide;
20 (15) Diampromide;
21 (16) Diethylthiambutene;
22 (17) Difenoxin;
23 (18) Dimenoxadol;
24 (19) Dimepheptanol;
25 (20) Dimethylthiambutene;
26 (21) Dioxaphetylbutyrate;
SB1987 - 26 - LRB103 25792 RLC 57149 b
SB1987- 27 -LRB103 25792 RLC 57149 b SB1987 - 27 - LRB103 25792 RLC 57149 b
SB1987 - 27 - LRB103 25792 RLC 57149 b
1 (22) Dipipanone;
2 (23) Ethylmethylthiambutene;
3 (24) Etonitazene;
4 (25) Etoxeridine;
5 (25.1) Flunitazene;
6
7 (26) Furethidine;
8 (27) Hydroxpethidine;
9 (27.1) Isotonitazene;
10 (28) Ketobemidone;
11 (29) Levomoramide;
12 (30) Levophenacylmorphan;
13 (31) 3-Methylfentanyl
14 (N-[3-methyl-1-(2-phenylethyl)-
15 4-piperidyl]-N-phenylpropanamide);
16 (31.1) 3-Methylthiofentanyl
17 (N-[(3-methyl-1-(2-thienyl)ethyl-
18 4-piperidinyl]-N-phenylpropanamide);
19 (31.2) Metonitazene;
20 (32) Morpheridine;
21 (33) Noracymethadol;
22 (34) Norlevorphanol;
23 (35) Normethadone;
24 (36) Norpipanone;
25 (36.1) Para-fluorofentanyl
26 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
SB1987 - 27 - LRB103 25792 RLC 57149 b
SB1987- 28 -LRB103 25792 RLC 57149 b SB1987 - 28 - LRB103 25792 RLC 57149 b
SB1987 - 28 - LRB103 25792 RLC 57149 b
1 4-piperidinyl]propanamide);
2 (37) Phenadoxone;
3 (38) Phenampromide;
4 (39) Phenomorphan;
5 (40) Phenoperidine;
6 (41) Piritramide;
7 (42) Proheptazine;
8 (43) Properidine;
9 (44) Propiram;
10 (45) Racemoramide;
11 (45.1) Thiofentanyl
12 (N-phenyl-N-[1-(2-thienyl)ethyl-
13 4-piperidinyl]-propanamide);
14 (46) Tilidine;
15 (47) Trimeperidine;
16 (48) Beta-hydroxy-3-methylfentanyl (other name:
17 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
18 N-phenylpropanamide);
19 (49) Furanyl fentanyl (FU-F);
20 (50) Butyryl fentanyl;
21 (51) Valeryl fentanyl;
22 (52) Acetyl fentanyl;
23 (53) Beta-hydroxy-thiofentanyl;
24 (54) 3,4-dichloro-N-[2-
25 (dimethylamino)cyclohexyl]-N-
26 methylbenzamide (U-47700);
SB1987 - 28 - LRB103 25792 RLC 57149 b
SB1987- 29 -LRB103 25792 RLC 57149 b SB1987 - 29 - LRB103 25792 RLC 57149 b
SB1987 - 29 - LRB103 25792 RLC 57149 b
1 (55) 4-chloro-N-[1-[2-
2 (4-nitrophenyl)ethyl]-2-piperidinylidene]-
3 benzenesulfonamide (W-18);
4 (56) 4-chloro-N-[1-(2-phenylethyl)
5 -2-piperidinylidene]-benzenesulfonamide (W-15);
6 (57) acrylfentanyl (acryloylfentanyl).
7 (c) Unless specifically excepted or unless listed in
8 another schedule, any of the following opium derivatives, its
9 salts, isomers and salts of isomers, whenever the existence of
10 such salts, isomers and salts of isomers is possible within
11 the specific chemical designation:
12 (1) Acetorphine;
13 (2) Acetyldihydrocodeine;
14 (3) Benzylmorphine;
15 (4) Codeine methylbromide;
16 (5) Codeine-N-Oxide;
17 (6) Cyprenorphine;
18 (7) Desomorphine;
19 (8) Diacetyldihydromorphine (Dihydroheroin);
20 (9) Dihydromorphine;
21 (10) Drotebanol;
22 (11) Etorphine (except hydrochloride salt);
23 (12) Heroin;
24 (13) Hydromorphinol;
25 (14) Methyldesorphine;
26 (15) Methyldihydromorphine;
SB1987 - 29 - LRB103 25792 RLC 57149 b
SB1987- 30 -LRB103 25792 RLC 57149 b SB1987 - 30 - LRB103 25792 RLC 57149 b
SB1987 - 30 - LRB103 25792 RLC 57149 b
1 (16) Morphine methylbromide;
2 (17) Morphine methylsulfonate;
3 (18) Morphine-N-Oxide;
4 (19) Myrophine;
5 (20) Nicocodeine;
6 (21) Nicomorphine;
7 (22) Normorphine;
8 (23) Pholcodine;
9 (24) Thebacon.
10 (d) Unless specifically excepted or unless listed in
11 another schedule, any material, compound, mixture, or
12 preparation which contains any quantity of the following
13 hallucinogenic substances, or which contains any of its salts,
14 isomers and salts of isomers, whenever the existence of such
15 salts, isomers, and salts of isomers is possible within the
16 specific chemical designation (for the purposes of this
17 paragraph only, the term "isomer" includes the optical,
18 position and geometric isomers):
19 (1) 3,4-methylenedioxyamphetamine
20 (alpha-methyl,3,4-methylenedioxyphenethylamine,
21 methylenedioxyamphetamine, MDA);
22 (1.1) Alpha-ethyltryptamine
23 (some trade or other names: etryptamine;
24 MONASE; alpha-ethyl-1H-indole-3-ethanamine;
25 3-(2-aminobutyl)indole; a-ET; and AET);
26 (2) 3,4-methylenedioxymethamphetamine (MDMA);
SB1987 - 30 - LRB103 25792 RLC 57149 b
SB1987- 31 -LRB103 25792 RLC 57149 b SB1987 - 31 - LRB103 25792 RLC 57149 b
SB1987 - 31 - LRB103 25792 RLC 57149 b
1 (2.1) 3,4-methylenedioxy-N-ethylamphetamine
2 (also known as: N-ethyl-alpha-methyl-
3 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
4 and MDEA);
5 (2.2) (Blank); N-Benzylpiperazine (BZP);
6 (2.2-1) (Blank); Trifluoromethylphenylpiperazine
7 (TFMPP);
8 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
9 (4) 3,4,5-trimethoxyamphetamine (TMA);
10 (5) (Blank);
11 (6) Diethyltryptamine (DET);
12 (7) Dimethyltryptamine (DMT);
13 (7.1) 5-Methoxy-diallyltryptamine;
14 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
15 (9) Ibogaine (some trade and other names:
16 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
17 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
18 indole; Tabernanthe iboga);
19 (10) Lysergic acid diethylamide;
20 (10.1) Salvinorin A;
21 (10.5) Salvia divinorum (meaning all parts of the
22 plant presently classified botanically as Salvia
23 divinorum, whether growing or not, the seeds thereof, any
24 extract from any part of that plant, and every compound,
25 manufacture, salts, isomers, and salts of isomers whenever
26 the existence of such salts, isomers, and salts of isomers
SB1987 - 31 - LRB103 25792 RLC 57149 b
SB1987- 32 -LRB103 25792 RLC 57149 b SB1987 - 32 - LRB103 25792 RLC 57149 b
SB1987 - 32 - LRB103 25792 RLC 57149 b
1 is possible within the specific chemical designation,
2 derivative, mixture, or preparation of that plant, its
3 seeds or extracts);
4 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
5 (12) Peyote (meaning all parts of the plant presently
6 classified botanically as Lophophora williamsii Lemaire,
7 whether growing or not, the seeds thereof, any extract
8 from any part of that plant, and every compound,
9 manufacture, salts, derivative, mixture, or preparation of
10 that plant, its seeds or extracts);
11 (13) N-ethyl-3-piperidyl benzilate (JB 318);
12 (14) N-methyl-3-piperidyl benzilate;
13 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
14 (also known as N-hydroxy-alpha-methyl-
15 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
16 (15) Parahexyl; some trade or other names:
17 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
18 dibenzo (b,d) pyran; Synhexyl;
19 (16) Psilocybin;
20 (17) Psilocyn;
21 (18) Alpha-methyltryptamine (AMT);
22 (19) 2,5-dimethoxyamphetamine
23 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
24 (20) 4-bromo-2,5-dimethoxyamphetamine
25 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
26 4-bromo-2,5-DMA);
SB1987 - 32 - LRB103 25792 RLC 57149 b
SB1987- 33 -LRB103 25792 RLC 57149 b SB1987 - 33 - LRB103 25792 RLC 57149 b
SB1987 - 33 - LRB103 25792 RLC 57149 b
1 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
2 Some trade or other names: 2-(4-bromo-
3 2,5-dimethoxyphenyl)-1-aminoethane;
4 alpha-desmethyl DOB, 2CB, Nexus;
5 (21) 4-methoxyamphetamine
6 (4-methoxy-alpha-methylphenethylamine;
7 paramethoxyamphetamine; PMA);
8 (22) (Blank);
9 (23) Ethylamine analog of phencyclidine.
10 Some trade or other names:
11 N-ethyl-1-phenylcyclohexylamine,
12 (1-phenylcyclohexyl) ethylamine,
13 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
14 (24) Pyrrolidine analog of phencyclidine. Some trade
15 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
16 PHP;
17 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
18 (26) 2,5-dimethoxy-4-ethylamphetamine
19 (another name: DOET);
20 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
21 (another name: TCPy);
22 (28) (Blank);
23 (29) Thiophene analog of phencyclidine (some trade
24 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
25 2-thienyl analog of phencyclidine; TPCP; TCP);
26 (29.1) Benzothiophene analog of phencyclidine. Some
SB1987 - 33 - LRB103 25792 RLC 57149 b
SB1987- 34 -LRB103 25792 RLC 57149 b SB1987 - 34 - LRB103 25792 RLC 57149 b
SB1987 - 34 - LRB103 25792 RLC 57149 b
1 trade or other names: BTCP or benocyclidine;
2 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
3 (30) Bufotenine (some trade or other names:
4 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
5 3-(2-dimethylaminoethyl)-5-indolol;
6 5-hydroxy-N,N-dimethyltryptamine;
7 N,N-dimethylserotonin; mappine);
8 (31) (Blank);
9 (32) (Blank);
10 (33) (Blank);
11 (34) (Blank);
12 (34.5) (Blank);
13 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
14 (2-methyloctan-2-yl)-6a,7,
15 10,10a-tetrahydrobenzo[c]chromen-1-ol
16 Some trade or other names: HU-210;
17 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
18 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
19 tetrahydrobenzo[c]chromen-1-ol, its isomers,
20 salts, and salts of isomers; Some trade or other
21 names: HU-210, Dexanabinol;
22 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
23 6,6-dimethyl-3-(2-methyloctan-2-yl)-
24 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
25 Some trade or other names: HU-211;
26 (37) (Blank);
SB1987 - 34 - LRB103 25792 RLC 57149 b
SB1987- 35 -LRB103 25792 RLC 57149 b SB1987 - 35 - LRB103 25792 RLC 57149 b
SB1987 - 35 - LRB103 25792 RLC 57149 b
1 (38) (Blank);
2 (39) (Blank);
3 (40) (Blank);
4 (41) (Blank);
5 (42) (Blank); Any compound structurally derived from
6 3-(1-naphthoyl)indole or
7 1H-indol-3-yl-(1-naphthyl)methane by substitution at the
8 nitrogen atom of the indole ring by alkyl, haloalkyl,
9 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
10 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
11 2-(4-morpholinyl)ethyl whether or not further substituted
12 in the indole ring to any extent, whether or not
13 substituted in the naphthyl ring to any extent. Examples
14 of this structural class include, but are not limited to,
15 JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
16 (43) (Blank); Any compound structurally derived from
17 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
18 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
19 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
20 halide, 1-(N-methyl-2-piperidinyl)methyl, or
21 2-(4-morpholinyl)ethyl, whether or not further substituted
22 in the pyrrole ring to any extent, whether or not
23 substituted in the naphthyl ring to any extent. Examples
24 of this structural class include, but are not limited to,
25 JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
26 (44) (Blank); Any compound structurally derived from
SB1987 - 35 - LRB103 25792 RLC 57149 b
SB1987- 36 -LRB103 25792 RLC 57149 b SB1987 - 36 - LRB103 25792 RLC 57149 b
SB1987 - 36 - LRB103 25792 RLC 57149 b
1 1-(1-naphthylmethyl)indene by substitution at the
2 3-position of the indene ring by alkyl, haloalkyl,
3 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
4 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
5 2-(4-morpholinyl)ethyl whether or not further substituted
6 in the indene ring to any extent, whether or not
7 substituted in the naphthyl ring to any extent. Examples
8 of this structural class include, but are not limited to,
9 JWH-176;
10 (45) (Blank); Any compound structurally derived from
11 3-phenylacetylindole by substitution at the nitrogen atom
12 of the indole ring with alkyl, haloalkyl, alkenyl,
13 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
14 halide, 1-(N-methyl-2-piperidinyl)methyl, or
15 2-(4-morpholinyl)ethyl, whether or not further substituted
16 in the indole ring to any extent, whether or not
17 substituted in the phenyl ring to any extent. Examples of
18 this structural class include, but are not limited to,
19 JWH-167, JWH-250, JWH-251, and RCS-8;
20 (46) (Blank); Any compound structurally derived from
21 2-(3-hydroxycyclohexyl)phenol by substitution at the
22 5-position of the phenolic ring by alkyl, haloalkyl,
23 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
24 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
25 2-(4-morpholinyl)ethyl, whether or not substituted in the
26 cyclohexyl ring to any extent. Examples of this structural
SB1987 - 36 - LRB103 25792 RLC 57149 b
SB1987- 37 -LRB103 25792 RLC 57149 b SB1987 - 37 - LRB103 25792 RLC 57149 b
SB1987 - 37 - LRB103 25792 RLC 57149 b
1 class include, but are not limited to, CP 47, 497 and its
2 C8 homologue (cannabicyclohexanol);
3 (46.1) (Blank); Any compound structurally derived from
4 3-(benzoyl) indole with substitution at the nitrogen atom
5 of the indole ring by an alkyl, haloalkyl, alkenyl,
6 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
7 halide, 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl group whether or not further
9 substituted in the indole ring to any extent and whether
10 or not substituted in the phenyl ring to any extent.
11 Examples of this structural class include, but are not
12 limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN
13 48,098), and RCS-4;
14 (47) (Blank);
15 (48) (Blank);
16 (49) (Blank);
17 (50) (Blank);
18 (51) (Blank);
19 (52) (Blank);
20 (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
21 Some trade or other names: 2C-T-7;
22 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
23 trade or other names: 2C-E;
24 (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
25 trade or other names: 2C-D;
26 (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
SB1987 - 37 - LRB103 25792 RLC 57149 b
SB1987- 38 -LRB103 25792 RLC 57149 b SB1987 - 38 - LRB103 25792 RLC 57149 b
SB1987 - 38 - LRB103 25792 RLC 57149 b
1 trade or other names: 2C-C;
2 (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
3 or other names: 2C-I;
4 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
5 trade or other names: 2C-T-2;
6 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
7 Some trade or other names: 2C-T-4;
8 (53.7) 2,5-dimethoxyphenethylamine. Some trade or
9 other names: 2C-H;
10 (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
11 trade or other names: 2C-N;
12 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
13 trade or other names: 2C-P;
14 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
15 Some trade or other names: 2C-G;
16 (53.11) The N-(2-methoxybenzyl) derivative of any 2C
17 phenethylamine referred to in subparagraphs (20.1), (53),
18 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
19 (53.8), (53.9), and (53.10) including, but not limited to,
20 25I-NBOMe and 25C-NBOMe;
21 (54) 5-Methoxy-N,N-diisopropyltryptamine;
22 (55) (Blank);
23 (56) (Blank);
24 (57) (Blank);
25 (58) (Blank);
26 (59) (Blank); 3-cyclopropoylindole with substitution
SB1987 - 38 - LRB103 25792 RLC 57149 b
SB1987- 39 -LRB103 25792 RLC 57149 b SB1987 - 39 - LRB103 25792 RLC 57149 b
SB1987 - 39 - LRB103 25792 RLC 57149 b
1 at the nitrogen atom of the indole ring by alkyl,
2 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
3 aryl halide, alkyl aryl halide,
4 1-(N-methyl-2-piperidinyl)methyl, or
5 2-(4-morpholinyl)ethyl, whether or not further substituted
6 on the indole ring to any extent, whether or not
7 substituted on the cyclopropyl ring to any extent:
8 including, but not limited to, XLR11, UR144, FUB-144;
9 (60) (Blank); 3-adamantoylindole with substitution at
10 the nitrogen atom of the indole ring by alkyl, haloalkyl,
11 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
12 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
13 2-(4-morpholinyl)ethyl, whether or not further substituted
14 on the indole ring to any extent, whether or not
15 substituted on the adamantyl ring to any extent:
16 including, but not limited to, AB-001;
17 (61) (Blank); N-(adamantyl)-indole-3-carboxamide with
18 substitution at the nitrogen atom of the indole ring by
19 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
20 cycloalkylethyl, aryl halide, alkyl aryl halide,
21 1-(N-methyl-2-piperidinyl)methyl, or
22 2-(4-morpholinyl)ethyl, whether or not further substituted
23 on the indole ring to any extent, whether or not
24 substituted on the adamantyl ring to any extent:
25 including, but not limited to, APICA/2NE-1, STS-135;
26 (62) (Blank); N-(adamantyl)-indazole-3-carboxamide
SB1987 - 39 - LRB103 25792 RLC 57149 b
SB1987- 40 -LRB103 25792 RLC 57149 b SB1987 - 40 - LRB103 25792 RLC 57149 b
SB1987 - 40 - LRB103 25792 RLC 57149 b
1 with substitution at a nitrogen atom of the indazole ring
2 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
3 cycloalkylethyl, aryl halide, alkyl aryl halide,
4 1-(N-methyl-2-piperidinyl)methyl, or
5 2-(4-morpholinyl)ethyl, whether or not further substituted
6 on the indazole ring to any extent, whether or not
7 substituted on the adamantyl ring to any extent:
8 including, but not limited to, AKB48, 5F-AKB48;
9 (63) (Blank); 1H-indole-3-carboxylic acid
10 8-quinolinyl ester with substitution at the nitrogen atom
11 of the indole ring by alkyl, haloalkyl, alkenyl,
12 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
13 halide, 1-(N-methyl-2-piperidinyl)methyl, or
14 2-(4-morpholinyl)ethyl, whether or not further substituted
15 on the indole ring to any extent, whether or not
16 substituted on the quinoline ring to any extent:
17 including, but not limited to, PB22, 5F-PB22, FUB-PB-22;
18 (64) (Blank); 3-(1-naphthoyl)indazole with
19 substitution at the nitrogen atom of the indazole ring by
20 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
21 cycloalkylethyl, aryl halide, alkyl aryl halide,
22 1-(N-methyl-2-piperidinyl)methyl, or
23 2-(4-morpholinyl)ethyl, whether or not further substituted
24 on the indazole ring to any extent, whether or not
25 substituted on the naphthyl ring to any extent: including,
26 but not limited to, THJ-018, THJ-2201;
SB1987 - 40 - LRB103 25792 RLC 57149 b
SB1987- 41 -LRB103 25792 RLC 57149 b SB1987 - 41 - LRB103 25792 RLC 57149 b
SB1987 - 41 - LRB103 25792 RLC 57149 b
1 (65) (Blank); 2-(1-naphthoyl)benzimidazole with
2 substitution at the nitrogen atom of the benzimidazole
3 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
4 cycloalkylethyl, aryl halide, alkyl aryl halide,
5 1-(N-methyl-2-piperidinyl)methyl, or
6 2-(4-morpholinyl)ethyl, whether or not further substituted
7 on the benzimidazole ring to any extent, whether or not
8 substituted on the naphthyl ring to any extent: including,
9 but not limited to, FUBIMINA;
10 (66) (Blank);
11 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
12 3-carboxamide with substitution on the nitrogen atom of
13 the indazole ring by alkyl, haloalkyl, alkenyl,
14 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
15 halide, 1-(N-methyl-2-piperidinyl)methyl, or
16 2-(4-morpholinyl)ethyl, whether or not further substituted
17 on the indazole ring to any extent: including, but not
18 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;
19 (67) (Blank);
20 N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
21 indazole-3-carboxamide with substitution on the nitrogen
22 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
23 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
24 halide, 1-(N-methyl-2-piperidinyl)methyl, or
25 2-(4-morpholinyl)ethyl, whether or not further substituted
26 on the indazole ring to any extent: including, but not
SB1987 - 41 - LRB103 25792 RLC 57149 b
SB1987- 42 -LRB103 25792 RLC 57149 b SB1987 - 42 - LRB103 25792 RLC 57149 b
SB1987 - 42 - LRB103 25792 RLC 57149 b
1 limited to, ADB-PINACA, ADB-FUBINACA;
2 (68) (Blank);
3 N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
4 indole-3-carboxamide with substitution on the nitrogen
5 atom of the indole ring by alkyl, haloalkyl, alkenyl,
6 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
7 halide, 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl, whether or not further substituted
9 on the indole ring to any extent: including, but not
10 limited to, ADBICA, 5F-ADBICA;
11 (69) (Blank);
12 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
13 3-carboxamide with substitution on the nitrogen atom of
14 the indole ring by alkyl, haloalkyl, alkenyl,
15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
16 halide, 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl, whether or not further substituted
18 on the indole ring to any extent: including, but not
19 limited to, ABICA, 5F-ABICA;
20 (70) (Blank); Methyl 2-(1H-indazole-3-carboxamido)-3-
21 methylbutanoate with substitution on the nitrogen atom of
22 the indazole ring by alkyl, haloalkyl, alkenyl,
23 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
24 halide, 1-(N-methyl-2-piperidinyl)methyl, or
25 2-(4-morpholinyl)ethyl, whether or not further substituted
26 on the indazole ring to any extent: including, but not
SB1987 - 42 - LRB103 25792 RLC 57149 b
SB1987- 43 -LRB103 25792 RLC 57149 b SB1987 - 43 - LRB103 25792 RLC 57149 b
SB1987 - 43 - LRB103 25792 RLC 57149 b
1 limited to, AMB, 5F-AMB;
2 (71) (Blank);
3 Methyl 2-(1H-indazole-3-carboxamido)-3,3-
4 dimethylbutanoate with substitution on the nitrogen atom
5 of the indazole ring by alkyl, haloalkyl, alkenyl,
6 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
7 halide, 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl, whether or not further substituted
9 on the indazole ring to any extent: including, but not
10 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
11 (72) (Blank); Methyl 2-(1H-indole-3-carboxamido)-3-
12 methylbutanoate with substitution on the nitrogen atom of
13 the indole ring by alkyl, haloalkyl, alkenyl,
14 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
15 halide, 1-(N-methyl-2-piperidinyl)methyl, or
16 2-(4-morpholinyl)ethyl, whether or not further substituted
17 on the indazole ring to any extent: including, but not
18 limited to, MMB018, MMB2201, and AMB-CHMICA;
19 (73) (Blank); Methyl 2-(1H-indole-3-carboxamido)-3,3-
20 dimethylbutanoate with substitution on the nitrogen atom
21 of the indole ring by alkyl, haloalkyl, alkenyl,
22 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
23 halide, 1-(N-methyl-2-piperidinyl)methyl, or
24 2-(4-morpholinyl)ethyl, whether or not further substituted
25 on the indazole ring to any extent: including, but not
26 limited to, MDMB-CHMICA;
SB1987 - 43 - LRB103 25792 RLC 57149 b
SB1987- 44 -LRB103 25792 RLC 57149 b SB1987 - 44 - LRB103 25792 RLC 57149 b
SB1987 - 44 - LRB103 25792 RLC 57149 b
1 (74) (Blank);
2 N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
3 indazole-3-carboxamide with substitution on the nitrogen
4 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
5 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
6 halide, 1-(N-methyl-2-piperidinyl)methyl, or
7 2-(4-morpholinyl)ethyl, whether or not further substituted
8 on the indazole ring to any extent: including, but not
9 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;
10 (75) (Blank);
11 N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
12 3-carboxamide with substitution on the nitrogen atom of
13 the indole ring by alkyl, haloalkyl, alkenyl,
14 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
15 halide, 1-(N-methyl-2-piperidinyl)methyl, or
16 2-(4-morpholinyl)ethyl, whether or not further substituted
17 on the indazole ring to any extent: including, but not
18 limited to, APP-PICA and 5-fluoro-APP-PICA;
19 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
20 4-AcO-DMT;
21 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
22 name 5-MeO-MIPT;
23 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
24 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
25 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
26 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
SB1987 - 44 - LRB103 25792 RLC 57149 b
SB1987- 45 -LRB103 25792 RLC 57149 b SB1987 - 45 - LRB103 25792 RLC 57149 b
SB1987 - 45 - LRB103 25792 RLC 57149 b
1 (4-HO-MiPT);
2 (82) (Blank); Fluorophenylpiperazine;
3 (83) Methoxetamine;
4 (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
5 ethcathinone).
6 (e) Unless specifically excepted or unless listed in
7 another schedule, any material, compound, mixture, or
8 preparation which contains any quantity of the following
9 substances having a depressant effect on the central nervous
10 system, including its salts, isomers, and salts of isomers
11 whenever the existence of such salts, isomers, and salts of
12 isomers is possible within the specific chemical designation:
13 (1) mecloqualone;
14 (2) methaqualone; and
15 (3) gamma hydroxybutyric acid.
16 (f) Unless specifically excepted or unless listed in
17 another schedule, any material, compound, mixture, or
18 preparation which contains any quantity of the following
19 substances having a stimulant effect on the central nervous
20 system, including its salts, isomers, and salts of isomers:
21 (1) Fenethylline;
22 (2) N-ethylamphetamine;
23 (3) Aminorex (some other names:
24 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
25 4-5-dihydro-5-phenyl-2-oxazolamine) and its
26 salts, optical isomers, and salts of optical isomers;
SB1987 - 45 - LRB103 25792 RLC 57149 b
SB1987- 46 -LRB103 25792 RLC 57149 b SB1987 - 46 - LRB103 25792 RLC 57149 b
SB1987 - 46 - LRB103 25792 RLC 57149 b
1 (4) Methcathinone (some other names:
2 2-methylamino-1-phenylpropan-1-one;
3 Ephedrone; 2-(methylamino)-propiophenone;
4 alpha-(methylamino)propiophenone; N-methylcathinone;
5 methycathinone; Monomethylpropion; UR 1431) and its
6 salts, optical isomers, and salts of optical isomers;
7 (5) Cathinone (some trade or other names:
8 2-aminopropiophenone; alpha-aminopropiophenone;
9 2-amino-1-phenyl-propanone; norephedrone);
10 (6) N,N-dimethylamphetamine (also known as:
11 N,N-alpha-trimethyl-benzeneethanamine;
12 N,N-alpha-trimethylphenethylamine);
13 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
14 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
15 (8) 3,4-Methylenedioxypyrovalerone (MDPV);
16 (9) Halogenated amphetamines and
17 methamphetamines - any compound derived from either
18 amphetamine or methamphetamine through the substitution
19 of a halogen on the phenyl ring, including, but not
20 limited to, 2-fluoroamphetamine, 3-
21 fluoroamphetamine and 4-fluoroamphetamine;
22 (10) Aminopropylbenzofuran (APB):
23 including 4-(2-Aminopropyl) benzofuran, 5-
24 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
25 benzofuran, and 7-(2-Aminopropyl) benzofuran;
26 (11) Aminopropyldihydrobenzofuran (APDB):
SB1987 - 46 - LRB103 25792 RLC 57149 b
SB1987- 47 -LRB103 25792 RLC 57149 b SB1987 - 47 - LRB103 25792 RLC 57149 b
SB1987 - 47 - LRB103 25792 RLC 57149 b
1 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
2 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
3 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
4 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;
5 (12) Methylaminopropylbenzofuran
6 (MAPB): including 4-(2-methylaminopropyl)
7 benzofuran, 5-(2-methylaminopropyl)benzofuran,
8 6-(2-methylaminopropyl)benzofuran
9 and 7-(2-methylaminopropyl)benzofuran; .
10 (13 Methylaminopropyldihydrobenzofuran (MAPDB):
11 including:
12 1-(2,3-dihydrobenzofuran-5-yl)-N-methylpropan-2-amine;
13 (g) Temporary listing of substances subject to emergency
14 scheduling. Any material, compound, mixture, or preparation
15 that contains any quantity of the following substances:
16 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
17 (benzylfentanyl), its optical isomers, isomers, salts, and
18 salts of isomers;
19 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
20 phenylpropanamide (thenylfentanyl), its optical isomers,
21 salts, and salts of isomers.
22 (h) Synthetic cathinones. Unless specifically excepted,
23 any chemical compound which is not approved by the United
24 States Food and Drug Administration or, if approved, is not
25 dispensed or possessed in accordance with State or federal
26 law, not including bupropion, structurally derived from
SB1987 - 47 - LRB103 25792 RLC 57149 b
SB1987- 48 -LRB103 25792 RLC 57149 b SB1987 - 48 - LRB103 25792 RLC 57149 b
SB1987 - 48 - LRB103 25792 RLC 57149 b
1 2-aminopropan-1-one by substitution at the 1-position with
2 either phenyl, naphthyl, or thiophene ring systems, whether or
3 not the compound is further modified in one or more of the
4 following ways:
5 (1) by substitution in the ring system to any extent
6 with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
7 halide substituents, whether or not further substituted in
8 the ring system by one or more other univalent
9 substituents. Examples of this class include, but are not
10 limited to, 3,4-Methylenedioxycathinone (bk-MDA);
11 (2) by substitution at the 3-position with an acyclic
12 alkyl substituent. Examples of this class include, but are
13 not limited to, 2-methylamino-1-phenylbutan-1-one
14 (buphedrone); or
15 (3) by substitution at the 2-amino nitrogen atom with
16 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
17 inclusion of the 2-amino nitrogen atom in a cyclic
18 structure. Examples of this class include, but are not
19 limited to, Dimethylcathinone, Ethcathinone, and
20 a-Pyrrolidinopropiophenone (a-PPP); or
21 Any other synthetic cathinone which is not approved by the
22 United States Food and Drug Administration or, if approved, is
23 not dispensed or possessed in accordance with State or federal
24 law.
25 (i) Synthetic cannabinoids or piperazines. Any synthetic
26 cannabinoid or piperazine which is not approved by the United
SB1987 - 48 - LRB103 25792 RLC 57149 b
SB1987- 49 -LRB103 25792 RLC 57149 b SB1987 - 49 - LRB103 25792 RLC 57149 b
SB1987 - 49 - LRB103 25792 RLC 57149 b
1 States Food and Drug Administration or, if approved, which is
2 not dispensed or possessed in accordance with State and
3 federal law.
4 (1) Synthetic cannabinoids include, but are not
5 limited to, compounds as identified in a report from an
6 accredited forensic laboratory, which are structurally
7 derived from the following compounds:
8 (1.1) 3-(1-naphthoyl)indole or
9 1H-indol-3-yl-(1-naphthyl)methane by substitution at
10 the nitrogen atom of the indole ring by alkyl,
11 haloalkyl, alkenyl, cycloalkylmethyl,
12 cycloalkylethyl, aryl halide, alkyl aryl halide,
13 1-(N-methyl-2-piperidinyl)methyl, or
14 2-(4-morpholinyl)ethyl whether or not further
15 substituted in the indole ring to any extent, whether
16 or not substituted in the naphthyl ring to any extent.
17 Examples of this structural class include, but are not
18 limited to, JWH-018, AM-2201, JWH-175, JWH-184, and
19 JWH-185;
20 (1.2) 3-(1-naphthoyl)pyrrole by substitution at
21 the nitrogen atom of the pyrrole ring by alkyl,
22 haloalkyl, alkenyl, cycloalkylmethyl,
23 cycloalkylethyl, aryl halide, alkyl aryl halide,
24 1-(N-methyl-2-piperidinyl)methyl, or
25 2-(4-morpholinyl)ethyl, whether or not further
26 substituted in the pyrrole ring to any extent, whether
SB1987 - 49 - LRB103 25792 RLC 57149 b
SB1987- 50 -LRB103 25792 RLC 57149 b SB1987 - 50 - LRB103 25792 RLC 57149 b
SB1987 - 50 - LRB103 25792 RLC 57149 b
1 or not substituted in the naphthyl ring to any extent.
2 Examples of this structural class include, but are not
3 limited to, JWH-030, JWH-145, JWH-146, JWH-307, and
4 JWH-368;
5 (1.3) Any compound structurally derived from
6 1-(1-naphthylmethyl)indene by substitution at the
7 3-position of the indene ring by alkyl, haloalkyl,
8 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
9 halide, alkyl aryl halide,
10 1-(N-methyl-2-piperidinyl)methyl, or
11 2-(4-morpholinyl)ethyl whether or not further
12 substituted in the indene ring to any extent, whether
13 or not substituted in the naphthyl ring to any extent.
14 Examples of this structural class include, but are not
15 limited to, JWH-176;
16 (1.4) Any compound structurally derived from
17 3-phenylacetylindole by substitution at the nitrogen
18 atom of the indole ring with alkyl, haloalkyl,
19 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
20 halide, alkyl aryl halide,
21 1-(N-methyl-2-piperidinyl)methyl, or
22 2-(4-morpholinyl)ethyl, whether or not further
23 substituted in the indole ring to any extent, whether
24 or not substituted in the phenyl ring to any extent.
25 Examples of this structural class include, but are not
26 limited to, JWH-167, JWH-250, JWH-251, and RCS-8;
SB1987 - 50 - LRB103 25792 RLC 57149 b
SB1987- 51 -LRB103 25792 RLC 57149 b SB1987 - 51 - LRB103 25792 RLC 57149 b
SB1987 - 51 - LRB103 25792 RLC 57149 b
1 (1.5) Any compound structurally derived from
2 2-(3-hydroxycyclohexyl)phenol by substitution at the
3 5-position of the phenolic ring by alkyl, haloalkyl,
4 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
5 halide, alkyl aryl halide,
6 1-(N-methyl-2-piperidinyl)methyl, or
7 2-(4-morpholinyl)ethyl, whether or not substituted in
8 the cyclohexyl ring to any extent. Examples of this
9 structural class include, but are not limited to, CP
10 47, 497 and its C8 homologue (cannabicyclohexanol);
11 (1.6) Any compound structurally derived from
12 3-(benzoyl) indole with substitution at the nitrogen
13 atom of the indole ring by an alkyl, haloalkyl,
14 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
15 halide, alkyl aryl halide,
16 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl group whether or not further
18 substituted in the indole ring to any extent and
19 whether or not substituted in the phenyl ring to any
20 extent. Examples of this structural class include, but
21 are not limited to, AM-630, AM-2233, AM-694,
22 Pravadoline (WIN 48,098), and RCS-4;
23 (1.7) 3-cyclopropoylindole with substitution at
24 the nitrogen atom of the indole ring by alkyl,
25 haloalkyl, alkenyl, cycloalkylmethyl,
26 cycloalkylethyl, aryl halide, alkyl aryl halide,
SB1987 - 51 - LRB103 25792 RLC 57149 b
SB1987- 52 -LRB103 25792 RLC 57149 b SB1987 - 52 - LRB103 25792 RLC 57149 b
SB1987 - 52 - LRB103 25792 RLC 57149 b
1 1-(N-methyl-2-piperidinyl)methyl, or
2 2-(4-morpholinyl)ethyl, whether or not further
3 substituted on the indole ring to any extent, whether
4 or not substituted on the cyclopropyl ring to any
5 extent: including, but not limited to, XLR11, UR144,
6 FUB-144;
7 (1.8) 3-adamantoylindole with substitution at the
8 nitrogen atom of the indole ring by alkyl, haloalkyl,
9 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
10 halide, alkyl aryl halide,
11 1-(N-methyl-2-piperidinyl)methyl, or
12 2-(4-morpholinyl)ethyl, whether or not further
13 substituted on the indole ring to any extent, whether
14 or not substituted on the adamantyl ring to any
15 extent: including, but not limited to, AB-001;
16 (1.9) N-(adamantyl)-indole-3-carboxamide with
17 substitution at the nitrogen atom of the indole ring
18 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
19 cycloalkylethyl, aryl halide, alkyl aryl halide,
20 1-(N-methyl-2-piperidinyl)methyl, or
21 2-(4-morpholinyl)ethyl, whether or not further
22 substituted on the indole ring to any extent, whether
23 or not substituted on the adamantyl ring to any
24 extent: including, but not limited to, APICA/2NE-1,
25 STS-135;
26 (1.10) N-(adamantyl)-indazole-3-carboxamide with
SB1987 - 52 - LRB103 25792 RLC 57149 b
SB1987- 53 -LRB103 25792 RLC 57149 b SB1987 - 53 - LRB103 25792 RLC 57149 b
SB1987 - 53 - LRB103 25792 RLC 57149 b
1 substitution at a nitrogen atom of the indazole ring
2 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
3 cycloalkylethyl, aryl halide, alkyl aryl halide,
4 1-(N-methyl-2-piperidinyl)methyl, or
5 2-(4-morpholinyl)ethyl, whether or not further
6 substituted on the indazole ring to any extent,
7 whether or not substituted on the adamantyl ring to
8 any extent: including, but not limited to, AKB48,
9 5F-AKB48;
10 (1.11) 1H-indole-3-carboxylic acid 8-quinolinyl
11 ester with substitution at the nitrogen atom of the
12 indole ring by alkyl, haloalkyl, alkenyl,
13 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
14 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
15 2-(4-morpholinyl)ethyl, whether or not further
16 substituted on the indole ring to any extent, whether
17 or not substituted on the quinoline ring to any
18 extent: including, but not limited to, PB22, 5F-PB22,
19 FUB-PB-22;
20 (1.12) 3-(1-naphthoyl)indazole with substitution
21 at the nitrogen atom of the indazole ring by alkyl,
22 haloalkyl, alkenyl, cycloalkylmethyl,
23 cycloalkylethyl, aryl halide, alkyl aryl halide,
24 1-(N-methyl-2-piperidinyl)methyl, or
25 2-(4-morpholinyl)ethyl, whether or not further
26 substituted on the indazole ring to any extent,
SB1987 - 53 - LRB103 25792 RLC 57149 b
SB1987- 54 -LRB103 25792 RLC 57149 b SB1987 - 54 - LRB103 25792 RLC 57149 b
SB1987 - 54 - LRB103 25792 RLC 57149 b
1 whether or not substituted on the naphthyl ring to any
2 extent: including, but not limited to, THJ-018,
3 THJ-2201;
4 (1.13) 2-(1-naphthoyl)benzimidazole with
5 substitution at the nitrogen atom of the benzimidazole
6 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
7 cycloalkylethyl, aryl halide, alkyl aryl halide,
8 1-(N-methyl-2-piperidinyl)methyl, or
9 2-(4-morpholinyl)ethyl, whether or not further
10 substituted on the benzimidazole ring to any extent,
11 whether or not substituted on the naphthyl ring to any
12 extent: including, but not limited to, FUBIMINA;
13 (1.14) N-(1-amino-3-methyl-1-oxobutan-2-yl)-
14 1H-indazole-3-carboxamide with substitution on the
15 nitrogen atom of the indazole ring by alkyl,
16 haloalkyl, alkenyl, cycloalkylmethyl,
17 cycloalkylethyl, aryl halide, alkyl aryl halide,
18 1-(N-methyl-2-piperidinyl)methyl, or
19 2-(4-morpholinyl)ethyl, whether or not further
20 substituted on the indazole ring to any extent:
21 including, but not limited to, AB-PINACA, AB-FUBINACA,
22 AB-CHMINACA;
23 (1.15) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-
24 1H-indazole-3-carboxamide with substitution on the
25 nitrogen atom of the indazole ring by alkyl,
26 haloalkyl, alkenyl, cycloalkylmethyl,
SB1987 - 54 - LRB103 25792 RLC 57149 b
SB1987- 55 -LRB103 25792 RLC 57149 b SB1987 - 55 - LRB103 25792 RLC 57149 b
SB1987 - 55 - LRB103 25792 RLC 57149 b
1 cycloalkylethyl, aryl halide, alkyl aryl halide,
2 1-(N-methyl-2-piperidinyl)methyl, or
3 2-(4-morpholinyl)ethyl, whether or not further
4 substituted on the indazole ring to any extent:
5 including, but not limited to, ADB-PINACA,
6 ADB-FUBINACA;
7 (1.16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-
8 1H-indole-3-carboxamide with substitution on the
9 nitrogen atom of the indole ring by alkyl, haloalkyl,
10 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
11 halide, alkyl aryl halide,
12 1-(N-methyl-2-piperidinyl)methyl, or
13 2-(4-morpholinyl)ethyl, whether or not further
14 substituted on the indole ring to any extent:
15 including, but not limited to, ADBICA, 5F-ADBICA;
16 (1.17) N-(1-amino-3-methyl-1-oxobutan-2-yl)-
17 1H-indole-3-carboxamide with substitution on the
18 nitrogen atom of the indole ring by alkyl, haloalkyl,
19 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
20 halide, alkyl aryl halide,
21 1-(N-methyl-2-piperidinyl)methyl, or
22 2-(4-morpholinyl)ethyl, whether or not further
23 substituted on the indole ring to any extent:
24 including, but not limited to, ABICA, 5F-ABICA;
25 (1.18) Methyl 2-(1H-indazole-3-carboxamido)-
26 3-methylbutanoate with substitution on the nitrogen
SB1987 - 55 - LRB103 25792 RLC 57149 b
SB1987- 56 -LRB103 25792 RLC 57149 b SB1987 - 56 - LRB103 25792 RLC 57149 b
SB1987 - 56 - LRB103 25792 RLC 57149 b
1 atom of the indazole ring by alkyl, haloalkyl,
2 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
3 halide, alkyl aryl halide,
4 1-(N-methyl-2-piperidinyl)methyl, or
5 2-(4-morpholinyl)ethyl, whether or not further
6 substituted on the indazole ring to any extent:
7 including, but not limited to, AMB, 5F-AMB;
8 (1.19) Methyl 2-(1H-indazole-3-carboxamido)-
9 3,3-dimethylbutanoate with substitution on the
10 nitrogen atom of the indazole ring by alkyl,
11 haloalkyl, alkenyl, cycloalkylmethyl,
12 cycloalkylethyl, aryl halide, alkyl aryl halide,
13 1-(N-methyl-2-piperidinyl)methyl, or
14 2-(4-morpholinyl)ethyl, whether or not further
15 substituted on the indazole ring to any extent:
16 including, but not limited to, 5-fluoro-MDMB-PINACA,
17 MDMB-FUBINACA;
18 (1.20) Methyl
19 2-(1H-indole-3-carboxamido)-3-methylbutanoate with
20 substitution on the nitrogen atom of the indole ring
21 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
22 cycloalkylethyl, aryl halide, alkyl aryl halide,
23 1-(N-methyl-2-piperidinyl)methyl, or
24 2-(4-morpholinyl)ethyl, whether or not further
25 substituted on the indole ring to any extent:
26 including, but not limited to, MMB018, MMB2201, and
SB1987 - 56 - LRB103 25792 RLC 57149 b
SB1987- 57 -LRB103 25792 RLC 57149 b SB1987 - 57 - LRB103 25792 RLC 57149 b
SB1987 - 57 - LRB103 25792 RLC 57149 b
1 AMB-CHMICA;
2 (1.21) Methyl 2-(1H-indole-3-carboxamido)-
3 3,3-dimethylbutanoate with substitution on the
4 nitrogen atom of the indole ring by alkyl, haloalkyl,
5 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
6 halide, alkyl aryl halide,
7 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl, whether or not further
9 substituted on the indole ring to any extent:
10 including, but not limited to, MDMB-CHMICA;
11 (1.22) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-
12 1H-indazole-3-carboxamide with substitution on the
13 nitrogen atom of the indazole ring by alkyl,
14 haloalkyl, alkenyl, cycloalkylmethyl,
15 cycloalkylethyl, aryl halide, alkyl aryl halide,
16 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl, whether or not further
18 substituted on the indazole ring to any extent:
19 including, but not limited to, APP-CHMINACA,
20 5-fluoro-APP-PINACA;
21 (1.23) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-
22 1H-indole-3-arboxamide with substitution on the
23 nitrogen atom of the indole ring by alkyl, haloalkyl,
24 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
25 halide, alkyl aryl halide,
26 1-(N-methyl-2-piperidinyl)methyl, or
SB1987 - 57 - LRB103 25792 RLC 57149 b
SB1987- 58 -LRB103 25792 RLC 57149 b SB1987 - 58 - LRB103 25792 RLC 57149 b
SB1987 - 58 - LRB103 25792 RLC 57149 b
1 2-(4-morpholinyl)ethyl, whether or not further
2 substituted on the indole ring to any extent:
3 including, but not limited to, APP-PICA and
4 5-fluoro-APP-PICA;
5 (1.24) 1H-indazole-3-carboxylic acid 8-quinolinyl
6 ester with substitution at the nitrogen atom of the
7 indazole ring by alkyl, haloalkyl, alkenyl,
8 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
9 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
10 2-(4-morpholinyl)ethyl, whether or not further
11 substituted on the inazdole ring to any extent,
12 whether or not substituted on the quinoline ring to
13 any extent: including, but not limited to, SDB-005,
14 5-F-SDB-005.
15 (2) Synthetic piperazines include, but are not limited
16 to the following compounds and their positional isomers:
17 (2.1) N-Benzylpiperazine (BZP);
18 (2.2) Trifluoromethylphenylpiperazine (TFMPP);
19 (2.3) Fluorophenylpiperazine;
20 (2.4) Chlorophenylpiperazine;
21 (j) Fentanyl-related substances.
22 (1) Fentanyl-related substance means any compound as
23 identified in a report from an accredited forensic
24 laboratory, unless specifically excepted or listed under
25 another schedule, which is not approved by the United
26 States Food and Drug Administration, or if approved, is
SB1987 - 58 - LRB103 25792 RLC 57149 b
SB1987- 59 -LRB103 25792 RLC 57149 b SB1987 - 59 - LRB103 25792 RLC 57149 b
SB1987 - 59 - LRB103 25792 RLC 57149 b
1 not dispensed or possessed in accordance with State or
2 Federal law, that is structurally derived from fentanyl
3 (N-phenyl-N-(1-(2-phenylethyl)-4-
4 piperidinyl)-propanamide) by one or more of the following
5 modifications:
6 (A) Replacement of the phenyl portion of the
7 phenethyl group by any monocycle, whether or not
8 further substituted in or on the monocycle;
9 (B) Substitution in or on the phenethyl group with
10 alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl,
11 amino or nitro groups;
12 (C) Substitution in or on the piperidine ring with
13 alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo,
14 haloalkyl, amino or nitro groups;
15 (D) Replacement of the aniline ring with any
16 aromatic monocycle whether or not further substituted
17 in or on the aromatic monocycle;
18 (E) Replacement of the N-propionyl group by
19 another acyl group.
20 (2) This definition includes, but is not limited to,
21 the following substances:
22 (2.1) Acetyl-alpha-methylfentanyl.
23 (2.2) Alpha-methylfentanyl (N-(1-alpha-methyl-
24 beta-phenyl) ethyl-4-piperidyl) propionanilide;
25 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine;
26 (2.3) Alpha-methylthiofentanyl (N-[1-methyl-2-
SB1987 - 59 - LRB103 25792 RLC 57149 b
SB1987- 60 -LRB103 25792 RLC 57149 b SB1987 - 60 - LRB103 25792 RLC 57149 b
SB1987 - 60 - LRB103 25792 RLC 57149 b
1 (2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
2 (2.4) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-
3 phenethyl)-4-piperidinyl]-N-phenylpropanamide;
4 (2.5) 3-Methylfentanyl (N-[3-methyl-1-
5 (2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);
6 (2.6) 3-Methylthiofentanyl (N-[(3-methyl-1-
7 (2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
8 (2.7) Para-fluorofentanyl (N-(4-fluorophenyl)-
9 N-[1-(2-phenethyl)-4-piperidinyl]propanamide);
10 (2.8) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-
11 4-piperidinyl]-propanamide);
12 (2.9) Beta-hydroxy-3-methylfentanyl (other name:
13 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
14 N-phenylpropanamide);
15 (2.10) Furanyl fentanyl (FU-F);
16 (2.11) Butyryl fentanyl;
17 (2.12) Valeryl fentanyl;
18 (2.13) Acetyl fentanyl;
19 (2.14) Beta-hydroxy-thiofentanyl;
20 (2.15) Acrylfentanyl (acryloylfentanyl);
21 (2.16) Cyclopropyl fentanyl;
22 (2.17) Crotonyl fentanyl;
23 (2.18) Methoxyacetyl fentanyl;
24 (2.19) Pentanoyl fentanyl;
25 (2.20) Cyclopentyl fentanyl;
26 (2.21) Isobutyryl fentanyl;
SB1987 - 60 - LRB103 25792 RLC 57149 b
SB1987- 61 -LRB103 25792 RLC 57149 b SB1987 - 61 - LRB103 25792 RLC 57149 b
SB1987 - 61 - LRB103 25792 RLC 57149 b
1 (2.22) Benzodioxolefentanyl;
2 (2.23) Tetrahydrofuran fentanyl.
3 (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
4 100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff.
5 8-14-18.)
6 (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)
7 Sec. 206. (a) The controlled substances listed in this
8 Section are included in Schedule II.
9 (b) Unless specifically excepted or unless listed in
10 another schedule, any of the following substances whether
11 produced directly or indirectly by extraction from substances
12 of vegetable origin, or independently by means of chemical
13 synthesis, or by combination of extraction and chemical
14 synthesis:
15 (1) Opium and opiates, and any salt, compound,
16 derivative or preparation of opium or opiate, excluding
17 apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
18 nalmefene, naloxone, and naltrexone, and their respective
19 salts, but including the following:
20 (i) Raw Opium;
21 (ii) Opium extracts;
22 (iii) Opium fluid extracts;
23 (iv) Powdered opium;
24 (v) Granulated opium;
25 (vi) Tincture of opium;
SB1987 - 61 - LRB103 25792 RLC 57149 b
SB1987- 62 -LRB103 25792 RLC 57149 b SB1987 - 62 - LRB103 25792 RLC 57149 b
SB1987 - 62 - LRB103 25792 RLC 57149 b
1 (vii) Codeine;
2 (viii) Ethylmorphine;
3 (ix) Etorphine Hydrochloride;
4 (x) Hydrocodone;
5 (xi) Hydromorphone;
6 (xii) Metopon;
7 (xiii) Morphine;
8 (xiii.5) 6-Monoacetylmorphine;
9 (xiv) Oxycodone;
10 (xv) Oxymorphone;
11 (xv.5) Tapentadol;
12 (xvi) Thebaine;
13 (xvii) Thebaine-derived butorphanol.
14 (xviii) Methorphan, except drug products
15 containing dextromethorphan that may be dispensed
16 pursuant to a prescription order of a practitioner and
17 are sold in compliance with the safety and labeling
18 standards as set forth by the United States Food and
19 Drug Administration, or drug products containing
20 dextromethorphan that are sold in solid, tablet,
21 liquid, capsule, powder, thin film, or gel form and
22 which are formulated, packaged, and sold in dosages
23 and concentrations for use as an over-the-counter drug
24 product. For the purposes of this Section,
25 "over-the-counter drug product" means a drug that is
26 available to consumers without a prescription and sold
SB1987 - 62 - LRB103 25792 RLC 57149 b
SB1987- 63 -LRB103 25792 RLC 57149 b SB1987 - 63 - LRB103 25792 RLC 57149 b
SB1987 - 63 - LRB103 25792 RLC 57149 b
1 in compliance with the safety and labeling standards
2 as set forth by the United States Food and Drug
3 Administration.
4 (2) Any salt, compound, isomer, derivative or
5 preparation thereof which is chemically equivalent or
6 identical with any of the substances referred to in
7 subparagraph (1), but not including the isoquinoline
8 alkaloids of opium;
9 (3) Opium poppy and poppy straw;
10 (4) Coca leaves and any salt, compound, isomer, salt
11 of an isomer, derivative, or preparation of coca leaves
12 including cocaine or ecgonine, and any salt, compound,
13 isomer, derivative, or preparation thereof which is
14 chemically equivalent or identical with any of these
15 substances, but not including decocainized coca leaves or
16 extractions of coca leaves which do not contain cocaine or
17 ecgonine (for the purpose of this paragraph, the term
18 "isomer" includes optical, positional and geometric
19 isomers);
20 (5) Concentrate of poppy straw (the crude extract of
21 poppy straw in either liquid, solid or powder form which
22 contains the phenanthrine alkaloids of the opium poppy).
23 (c) Unless specifically excepted or unless listed in
24 another schedule any of the following opiates, including their
25 isomers, esters, ethers, salts, and salts of isomers, whenever
26 the existence of these isomers, esters, ethers and salts is
SB1987 - 63 - LRB103 25792 RLC 57149 b
SB1987- 64 -LRB103 25792 RLC 57149 b SB1987 - 64 - LRB103 25792 RLC 57149 b
SB1987 - 64 - LRB103 25792 RLC 57149 b
1 possible within the specific chemical designation, dextrorphan
2 excepted:
3 (1) Alfentanil;
4 (1.1) Carfentanil;
5 (1.2) Thiafentanyl;
6 (2) Alphaprodine;
7 (3) Anileridine;
8 (4) Bezitramide;
9 (5) Bulk Dextropropoxyphene (non-dosage forms);
10 (6) Dihydrocodeine;
11 (7) Diphenoxylate;
12 (8) Fentanyl;
13 (9) Sufentanil;
14 (9.5) Remifentanil;
15 (10) Isomethadone;
16 (11) (Blank);
17 (12) Levorphanol (Levorphan);
18 (13) Metazocine;
19 (14) Methadone;
20 (15) Methadone-Intermediate,
21 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
22 (16) Moramide-Intermediate,
23 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
24 acid;
25 (17) Pethidine (meperidine);
26 (18) Pethidine-Intermediate-A,
SB1987 - 64 - LRB103 25792 RLC 57149 b
SB1987- 65 -LRB103 25792 RLC 57149 b SB1987 - 65 - LRB103 25792 RLC 57149 b
SB1987 - 65 - LRB103 25792 RLC 57149 b
1 4-cyano-1-methyl-4-phenylpiperidine;
2 (19) Pethidine-Intermediate-B,
3 ethyl-4-phenylpiperidine-4-carboxylate;
4 (20) Pethidine-Intermediate-C,
5 1-methyl-4-phenylpiperidine-4-carboxylic acid;
6 (21) Phenazocine;
7 (22) Piminodine;
8 (23) Racemethorphan;
9 (24) (Blank);
10 (25) Levo-alphacetylmethadol (some other names:
11 levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).
12 (d) Unless specifically excepted or unless listed in
13 another schedule, any material, compound, mixture, or
14 preparation which contains any quantity of the following
15 substances having a stimulant effect on the central nervous
16 system:
17 (1) Amphetamine, its salts, optical isomers, and salts
18 of its optical isomers;
19 (2) Methamphetamine, its salts, isomers, and salts of
20 its isomers;
21 (3) Phenmetrazine and its salts;
22 (4) Methylphenidate;
23 (5) Lisdexamfetamine.
24 (e) Unless specifically excepted or unless listed in
25 another schedule, any material, compound, mixture, or
26 preparation which contains any quantity of the following
SB1987 - 65 - LRB103 25792 RLC 57149 b
SB1987- 66 -LRB103 25792 RLC 57149 b SB1987 - 66 - LRB103 25792 RLC 57149 b
SB1987 - 66 - LRB103 25792 RLC 57149 b
1 substances having a depressant effect on the central nervous
2 system, including its salts, isomers, and salts of isomers
3 whenever the existence of such salts, isomers, and salts of
4 isomers is possible within the specific chemical designation:
5 (1) Amobarbital;
6 (2) Secobarbital;
7 (3) Pentobarbital;
8 (4) Pentazocine;
9 (5) Phencyclidine;
10 (6) Gluthethimide;
11 (7) (Blank).
12 (f) Unless specifically excepted or unless listed in
13 another schedule, any material, compound, mixture, or
14 preparation which contains any quantity of the following
15 substances:
16 (1) Immediate precursor to amphetamine and
17 methamphetamine:
18 (i) Phenylacetone
19 Some trade or other names: phenyl-2-propanone;
20 P2P; benzyl methyl ketone; methyl benzyl ketone.
21 (2) Immediate precursors to phencyclidine:
22 (i) 1-phenylcyclohexylamine;
23 (ii) 1-piperidinocyclohexanecarbonitrile (PCC).
24 (3) Nabilone.
25 (Source: P.A. 100-368, eff. 1-1-18.)
SB1987 - 66 - LRB103 25792 RLC 57149 b
SB1987- 67 -LRB103 25792 RLC 57149 b SB1987 - 67 - LRB103 25792 RLC 57149 b
SB1987 - 67 - LRB103 25792 RLC 57149 b
1 (720 ILCS 570/210) (from Ch. 56 1/2, par. 1210)
2 Sec. 210. (a) The controlled substances listed in this
3 Section are included in Schedule IV.
4 (b) Unless specifically excepted or unless listed in
5 another schedule, any material, compound, mixture, or
6 preparation containing limited quantities of any of the
7 following narcotic drugs, or their salts calculated as the
8 free anhydrous base or alkaloid, as set forth below:
9 (1) Not more than 1 milligram of difenoxin (DEA Drug
10 Code No. 9618) and not less than 25 micrograms of atropine
11 sulfate per dosage unit.
12 (2) Dextropropoxyphene (Alpha-(+)-4-dimethylamino-1,
13 2-diphenyl-3-methyl-2-propionoxybutane).
14 (c) Unless specifically excepted or unless listed in
15 another schedule, any material, compound, mixture, or
16 preparation which contains any quantity of the following
17 substances having a potential for abuse associated with a
18 depressant effect on the central nervous system:
19 (1) Alprazolam;
20 (2) Barbital;
21 (2.1) Bromazepam;
22 (2.2) Camazepam;
23 (2.3) Carisoprodol;
24 (3) Chloral Betaine;
25 (4) Chloral Hydrate;
26 (5) Chlordiazepoxide;
SB1987 - 67 - LRB103 25792 RLC 57149 b
SB1987- 68 -LRB103 25792 RLC 57149 b SB1987 - 68 - LRB103 25792 RLC 57149 b
SB1987 - 68 - LRB103 25792 RLC 57149 b
1 (5.1) Clobazam;
2 (6) Clonazepam;
3 (7) Clorazepate;
4 (7.1) Clotiazepam;
5 (7.2) Cloxazolam;
6 (7.3) Delorazepam;
7 (8) Diazepam;
8 (8.05) Dichloralphenazone;
9 (8.1) Estazolam;
10 (9) Ethchlorvynol;
11 (10) Ethinamate;
12 (10.1) Ethyl loflazepate;
13 (10.2) Fludiazepam;
14 (10.3) Flunitrazepam;
15 (11) Flurazepam;
16 (11.1) Fospropofol;
17 (12) Halazepam;
18 (12.1) Haloxazolam;
19 (12.2) Ketazolam;
20 (12.3) Loprazolam;
21 (13) Lorazepam;
22 (13.1) Lormetazepam;
23 (14) Mebutamate;
24 (14.1) Medazepam;
25 (15) Meprobamate;
26 (16) Methohexital;
SB1987 - 68 - LRB103 25792 RLC 57149 b
SB1987- 69 -LRB103 25792 RLC 57149 b SB1987 - 69 - LRB103 25792 RLC 57149 b
SB1987 - 69 - LRB103 25792 RLC 57149 b
1 (17) Methylphenobarbital (Mephobarbital);
2 (17.1) Midazolam;
3 (17.2) Nimetazepam;
4 (17.3) Nitrazepam;
5 (17.4) Nordiazepam;
6 (18) Oxazepam;
7 (18.1) Oxazolam;
8 (19) Paraldehyde;
9 (20) Petrichloral;
10 (21) Phenobarbital;
11 (21.1) Pinazepam;
12 (22) Prazepam;
13 (22.1) Quazepam;
14 (23) Temazepam;
15 (23.1) Tetrazepam;
16 (23.2) Tramadol;
17 (24) Triazolam;
18 (24.5) Zaleplon;
19 (25) Zolpidem;
20 (26) Zopiclone.
21 (1) Unless specifically excepted or listed in another
22 schedule, any chemical compound which is not approved by
23 the United States Food and Drug Administration or, if
24 approved, is not dispensed or possessed in accordance with
25 State or federal law, and is derived from the following
26 structural classes and their salts:
SB1987 - 69 - LRB103 25792 RLC 57149 b
SB1987- 70 -LRB103 25792 RLC 57149 b SB1987 - 70 - LRB103 25792 RLC 57149 b
SB1987 - 70 - LRB103 25792 RLC 57149 b
1 (A) Benzodiazepine class: A fused 1,4-diazepine
2 and benzene ring structure with a phenyl connected to
3 the 1,4-diazepine ring, with any substitution or
4 replacement on the 1,4-diazepine or benzene ring, any
5 substitution on the phenyl ring, or any combination
6 thereof. This definition includes, but is not limited
7 to, the following substances:
8 (1.A.1) Alprazolam;
9 (1.A.2) Bromazepam;
10 (1.A.3) Camazepam;
11 (1.A.4) Clobazam;
12 (1.A.5) Clonazepam;
13 (1.A.6) Clonazolam;
14 (1.A.7) Clorazepate;
15 (1.A.8) Delorazepam;
16 (1.A.9) Diazepam;
17 (1.A.10) Diclazepam;
18 (1.A.11) Estazolam;
19 (1.A.12) Ethyl loflazepate;
20 (1.A.13) Flualprazolam;
21 (1.A.14) Flubromazepam;
22 (1.A.15) Flubromazolam;
23 (1.A.16) Fludiazepam;
24 (1.A.17) Flunitrazepam;
25 (1.A.18) Flurazepam;
26 (1.A.19) Halazepam;
SB1987 - 70 - LRB103 25792 RLC 57149 b
SB1987- 71 -LRB103 25792 RLC 57149 b SB1987 - 71 - LRB103 25792 RLC 57149 b
SB1987 - 71 - LRB103 25792 RLC 57149 b
1 (1.A.20) Loprazolam;
2 (1.A.21) Lorazepam;
3 (1.A.22) Lormetazepam;
4 (1.A.23) Meclonazolam;
5 (1.A.24) Medazepam;
6 (1.A.25) Midazolam;
7 (1.A.26) Nimetazepam;
8 (1.A.27) Nitrazepam;
9 (1.A.28) Nordiazepam;
10 (1.A.29) Oxazepam;
11 (1.A.30) Pinazepam;
12 (1.A.31) Prazepam;
13 (1.A.32) Quazepam;
14 (1.A.33) Temazepam;
15 (1.A.34) Triazolam;
16 (B) Thienodiazepine class: A fused 1,4-diazepine
17 and thiophene ring structure with a phenyl connected
18 to the 1,4-diazepine ring, with any substitution or
19 replacement on the 1,4-diazepine or thiophene ring,
20 any substitution(s) on the phenyl ring, or any
21 combination thereof. This definition includes, but is
22 not limited to, the following substances:
23 (1.B.1) Clotiazepam;
24 (1.B.2) Etizolam;
25 (2) Barbital;
26 (3) Carisoprodol;
SB1987 - 71 - LRB103 25792 RLC 57149 b
SB1987- 72 -LRB103 25792 RLC 57149 b SB1987 - 72 - LRB103 25792 RLC 57149 b
SB1987 - 72 - LRB103 25792 RLC 57149 b
1 (4) Chloral Betaine;
2 (5) Chloral Hydrate;
3 (6) Chlordiazepoxide;
4 (7) Cloxazolam;
5 (8) Dichloralphenazone;
6 (9) Ethchlorvynol;
7 (10) Ethinamate;
8 (11) Fospropofol;
9 (12) Haloxazolam;
10 (13) Ketazolam;
11 (14) Mebutamate;
12 (15) Meprobamate;
13 (16) Methohexital;
14 (17) Methylphenobarbital (Mephobarbital);
15 (18) Oxazolam;
16 (19) Paraldehyde;
17 (20) Petrichloral;
18 (21) Phenobarbital;
19 (22) Tetrazepam;
20 (23) Tramadol;
21 (24) Zaleplon;
22 (25) Zolpidem;
23 (26) Zopiclone.
24 (d) Any material, compound, mixture, or preparation which
25 contains any quantity of the following substances, including
26 its salts, isomers (whether optical, position, or geometric),
SB1987 - 72 - LRB103 25792 RLC 57149 b
SB1987- 73 -LRB103 25792 RLC 57149 b SB1987 - 73 - LRB103 25792 RLC 57149 b
SB1987 - 73 - LRB103 25792 RLC 57149 b
1 and salts of such isomers, whenever the existence of such
2 salts, isomers and salts of isomers is possible:
3 (1) Fenfluramine.
4 (e) Unless specifically excepted or unless listed in
5 another schedule any material, compound, mixture, or
6 preparation which contains any quantity of the following
7 substances having a stimulant effect on the central nervous
8 system, including its salts, isomers (whether optical,
9 position or geometric), and salts of such isomers whenever the
10 existence of such salts, isomers, and salts of isomers is
11 possible within the specific chemical designation:
12 (1) Cathine ((+)-norpseudoephedrine);
13 (1.1) Diethylpropion;
14 (1.2) Fencamfamin;
15 (1.3) Fenproporex;
16 (2) Mazindol;
17 (2.1) Mefenorex;
18 (3) Phentermine;
19 (4) Pemoline (including organometallic complexes and
20 chelates thereof);
21 (5) Pipradrol;
22 (6) SPA ((-)-1-dimethylamino-1, 2-diphenylethane);
23 (7) Modafinil;
24 (8) Sibutramine.
25 (f) Other Substances. Unless specifically excepted or
26 unless listed in another schedule, any material, compound,
SB1987 - 73 - LRB103 25792 RLC 57149 b
SB1987- 74 -LRB103 25792 RLC 57149 b SB1987 - 74 - LRB103 25792 RLC 57149 b
SB1987 - 74 - LRB103 25792 RLC 57149 b
1 mixture, or preparation that contains any quantity of the
2 following substance, including its salts:
3 (1) Butorphanol (including its optical isomers).
4 (g) The Department may except by rule any compound,
5 mixture, or preparation containing any depressant substance
6 listed in subsection (b) from the application of all or any
7 part of this Act if the compound, mixture, or preparation
8 contains one or more active medicinal ingredients not having a
9 depressant effect on the central nervous system, and if the
10 admixtures are included therein in combinations, quantity,
11 proportion, or concentration that vitiate the potential for
12 abuse of the substances which have a depressant effect on the
13 central nervous system.
14 (h) Except as otherwise provided in Section 216, any
15 material, compound, mixture, or preparation that contains any
16 quantity of the following substance having a stimulant effect
17 on the central nervous system, including its salts,
18 enantiomers (optical isomers) and salts of enantiomers
19 (optical isomers):
20 (1) Ephedrine, its salts, optical isomers and salts of
21 optical isomers.
22 (Source: P.A. 97-334, eff. 1-1-12.)
SB1987 - 74 - LRB103 25792 RLC 57149 b